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1.1  PARKINSON’S DISEASE
1.1.1 History
Th e fi rst formal description of “Parkinson’s disease” dates back to 1817 (1) when James 
Parkinson published his monograph “An Essay on the Shaking Palsy” in which he descri-
bed six patients with an insidious onset of progressive symptoms, including a tremulous 
motion and a shuﬄ  ing gait, propensity to bend the trunk forward, general slowness, 
soft speech and “saliva trickling from the mouth”. However, he also acknowledged that 
there were notifi cations of a similar tremulous disease a long time before his observati-
ons. For example, ancient medical documents with descriptions resembling the shaking 
palsy’s symptoms dates back as far as the Neosumerian period (2012-2004 BC). Galen 
of Pergamon (129-200 AD) wrote a book called “De Tremore, Palpitatione, Convulsio-
ne et Rigore” in which he seem to distinguish resting (“palpitatione”) from intentional 
tremor (“tremore”) (2). Although James Parkinson described mostly motor features of 
the disease, he did mention some non-motor features like disturbed sleep and “torpid 
bowels” but stated that the senses and intellects were not aﬀ ected (1). Rigidity was later 
described by Charcot in 1872 and he proposed to call this disease Parkinson’s disease 
(3). For a long time, research mainly focused on the complexity of motor symptoms in 
PD, but the last two to three decades there is increasing awareness of the importance of 
non-motor symptoms, like anxiety and depression, and their impact on the quality of 
life of PD patients (4, 5). 
1.1.2  Epidemiology
At present, Parkinson’s disease is the second most common neurodegenerative disease, 
after Alzheimer disease (6). Th e prevalence of PD in industrialized countries is estimated 
at 0.3% of the entire population and about 1% in people over 60 years of age. Incidence 
rises steeply with age; 17.4 in 100 000 persons years between 50 and 59 to 93.1 in 100 
000 person years between 70 and 79 years (6-8). Mean age at onset is approximately 
60 years. Importantly, it is expected that due to the ageing population prevalence and 
incidence will increase, together with its social and economic burden. 
1.1.3 Etiology and pathogenesis
Although the exact cause of PD is still not known, it is generally accepted that it has a 
multifactorial origin in which environmental (9, 10) and genetic factors (11, 12) even-
tually lead to mitochondrial dysfunction, disturbance of proteolysis, protein aggregation 
and neuro-infl ammation, which are all important pathogenic factors for PD (13, 14). 
Th e pathological hallmark is the selective loss of dopaminergic neurons from the pars 
compacta of the substantia nigra, an anatomical structure located in the midbrain. It 
is estimated that at time of appearance of motor signs about 30% of total substantia 
nigra neurons is already lost (15). Th e cell loss is accompanied by intraneural inclusi-
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ons, mainly Lewy bodies that are composed principally of α-synuclein aggregates. In 
addition to the dopaminergic neuronal cell loss, there is also loss of the serotonergic, 
noradrenergic and acetylcholinergic neurons, which may explain the variation of motor 
and non-motor symptoms in PD (8, 15). 
1.1.4 Symptomatology
Th e four cardinal motor features, upon which the diagnosis of PD is currently based, 
include bradykinesia, muscle rigidity, resting tremor and postural instability (16). Ho-
wever, PD also encompasses a wide range of non-motor symptoms: neuropsychiatric 
disturbances, such as depression, anxiety, and hallucinations), autonomic disturbances, 
such as constipation, orthostatic hypotension, and bladder disturbances), sensory dis-
turbances, such as pain, olfactory loss, sleep disorders including vivid dreaming and 
REM-sleep disorders, and cognitive disturbances such as executive dysfunction and de-
mentia (5, 17, 18). Th ese Non-motor symptoms can develop at all stages of PD, alt-
hough some symptoms such as olfactory dysfunction and constipation are considered 
prodromal signs of PD (19). Non-motor symptoms are increasingly recognized as an 
important part of the clinical spectrum of PD, and a signifi cant cause of disability and 
poor quality of life in PD patients (4). 
 
1.1.5 Treatment
Th ere are currently no treatments that cure PD nor treatments with a proven neuro-
protective eﬀ ect which can slow down or stop progression of the disease (20). However, 
there are a number of symptomatic therapeutic options, mainly targeting motor symp-
toms that work by correcting the central dopaminergic defi cit.  Levodopa, a precursor 
of dopamine, is the most eﬀ ective and currently the gold standard for treating mo-
tor symptoms in PD, followed by dopamine agonists. Catechol-O-methyltransferase 
(COMT) inhibitors and monoamine oxidase B (MAO-B) inhibitors have been develo-
ped to provide more continuous oral delivery of dopaminergic stimulation, especially 
in patients with motor fl uctuations. In some cases, the anti-NMDA receptor antagonist 
amantadine can be useful in targeting motor symptoms (20-22).  In more advanced 
cases, neurosurgical interventions such as deep brain stimulation (DBS) and continuous 
dopamine replacement pump therapies such as subcutaneous apomorphine or levodo-
pa/carbidopa intestinal gel can be indicated to alleviate disabling motor symptoms (23, 
24). Despite their importance for patients’ quality of life, evidence based treatment is 
sparse for non-motor symptoms (25). Although non-motor symptoms can be dopamine 
responsive by replacement therapy to some extent, for several indications, like anxiety 
disorders, orthostatic hypotension or urinary dysfunction there is a lack of suitable in-
terventions at the moment (19, 26). In addition to pharmacologic treatment, patients 
can benefi t from physical therapy, speech therapy, occupational therapy or cognitive 
behavioral therapy (27-31).
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1.2 ANXIETY AND DEPRESSION IN PARKINSON’S DISEASE 
1.2.1 Neuropsychiatric disturbances in PD
Neuropsychiatric symptoms are the most frequent non-motor symptoms and occur in 
up to 67% of PD patients (4). Th e most common and most important non-motor 
features are depression, anxiety, apathy, fatigue, impulse control disorders, dopamine 
dysregulation syndrome and psychosis, which all have a negative eﬀ ect on quality of life 
(4, 32-34). Among those, mood and anxiety disorders are both frequent and disabling 
(35). Mood disorders encompasses a group of symptoms in which the person’s mood 
is the underlying feature, including major depressive disorder, dysthymic disorder and 
bipolar disorders (36). Together with disturbances in aﬀ ect, e.g. anxiety disorders, they 
have a detrimental infl uence on patient’s life, contributing to motor symptoms, motor 
complications, gait diﬃ  culties, cognitive impairment, poor self-perceived health status 
and even increased mortality (37-40). In addition, anxiety and depression commonly 
co-occur in PD (41-43). 
1.2.2 Depression in Parkinson’s disease
It is thought that depressive symptoms are the most common neuropsychiatric feature 
associated with Parkinson’s disease (44).  A thorough systematic review found a weighted 
prevalence of 17% major depressive disorder in PD patients, 22% minor depression and 
13% dysthymia, according to DSM criteria. Up to 35% have clinically relevant depres-
sive symptoms (45). It is a syndrome characterized by persistent sadness or anhedonia, 
with a range of cognitive and vital (physical) symptoms (36). Despite extensive research, 
there is still discussion about the optimal treatment strategy of depression in PD (46), 
but a large randomized, placebo controlled clinical trial found that both paroxetine and 
venlafaxine were more eﬀ ective than placebo for the treatment of depressive symptoms 
in PD (47). Additionally, there is some evidence for the use of nortriptyline, citalopram 
and cognitive-behavioral therapy in depressed PD patients (48-50). Depressive disor-
ders in PD develop in the context of multiple interacting risk and protective factors and 
are believed to aﬀ ect dopaminergic, serotonergic and noradrenergic systems (51).  A 
recent model of depression in PD showed that nonspecifi c factors (female sex, history of 
anxiety and/or depression, family history of depression, worse functioning on activity of 
daily living and worse cognitive status) might be more prominent markers of depression 
than PD-specifi c factors (increased disease duration, more severe motor symptoms and 
the use of levodopa) (52). It may be that PD patients that become depressed are those 
that already have a number of general risk factors for depression, that are not related to 
PD. 
Currently, depression is most commonly defi ned by the criteria of the DSM. A wide 
range of rating scales are available for screening or quantifi cation of symptoms, among 
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which the Beck Depression Inventory (BDI), Hamilton Depression Scale (HAMD), 
Hospital Anxiety and Depression Scale (HADS), Zung Self-Rating Depression Scale 
(SDS), Geriatric Depression scale (GDS) and Montgomery-Asberg Depression Rating 
Scale (MADRS) (53). However, up to 65% of depressive disorders remain undetected 
and untreated in PD (54). A possible explanation is the symptom overlap between PD 
and depression, for example fatigue, agitation, impaired concentration and insomnia 
are seen in both depression and PD. In addition, reliability and validity diﬀ er between 
rating scales (53) and some question the use of DSM criteria in depressed PD patients 
(55). As previously stated, depression has a negative impact on disability and quality of 
life but also negatively infl uence medication adherence (56). Improving detection and, 
when antidepressant treatment is initiated, improving treatment compliance could pos-
sibly increase quality of life and alleviate functional impairment in PD patients. 
1.2.3 Anxiety in Parkinson’s disease
Non-motor symptom research in PD has predominantly focused on depressive disor-
ders. Although anxiety syndromes seem to be common in PD, they have not been ex-
tensively studied (57). Prevalence rates of anxiety vary widely between 25 to 65% (38, 
40, 42). Next to clinically relevant anxiety symptoms assessed by rating scales, anxiety 
disorders are classifi ed by the DSM criteria. Th ey include generalized anxiety disorder 
(GAD), panic disorder, agoraphobia, obsessive-compulsive disorder (OCD), social or 
specifi c phobia, posttraumatic stress disorder (PTSS), and anxiety not otherwise speci-
fi ed (NOS) (36). Th e latter category is often used to describe signifi cant anxiety that do 
not meet criteria for a standard DSM anxiety disorder. Anxiety disorders contribute to 
cognitive impairment and increased severity of motor symptoms such as on/oﬀ  fl uctua-
tions or freezing episodes (38, 40, 41, 58). Anxiety also has a negative impact on quality 
of life, some state even more so than depression (39, 40). Currently, there is a paucity 
of treatment data for anxiety in PD and treatments include benzodiazepines, SSRI’s or 
cognitive and behavioral therapies (59). Th e relationship between anxiety and PD is 
not well understood but likely involves dopaminergic, noradrenergic and serotonergic 
neurotransmitter systems (57). As for depression and anxiety in the general population, 
anxiety disorders in PD develop in the context of multiple interacting risk and protec-
tive factors. Although some PD-specifi c risk factors for anxiety have been identifi ed in 
some studies, including younger age of PD motor symptom onset, motor fl uctuations, 
high dose of antiparkinsonian medication, longer disease duration and disease severity 
(41, 60-62), other studies found no signifi cant associating between these variables and 
anxiety (42, 63-65). Only a few studies have investigated the role of general risk factors 
for PD, like female gender, younger age and a history of anxiety or depression (41, 42, 
65).  
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As for depression, similar issues exist for anxiety in PD. It is often underdiagnosed and 
some studies have indicated that over half of the clinically signifi cant anxiety cases are 
not recognized by clinicians (66, 67). In addition, frequent used anxiety rating scales 
are criticized and somatic symptoms of anxiety show overlap with those of PD, making 
identifi cation of anxiety in PD diﬃ  cult (68). Increased awareness and knowledge about 
the phenomenon of anxiety in PD is required to improve the accuracy of diagnosis, 
subsequent treatment and ultimately a better quality of life for PD patients. 
1.3 AIM AND OUTLINE OF THIS THESIS
Th e main aim of this thesis was to investigate conceptual and clinical aspects of anxiety 
(Chapter 2 and 3) and depression (Chapter 4 and 5) in Parkinson’s disease, alongside 
testing the feasibility of a new method (Chapter 6) to further unravel the complexity of 
these non-motor symptoms in the future.  
Since there is no agreement on the prevalence of anxiety and anxiety in PD, in Chapter 
2, we conduct a systematic review and meta-analysis to calculate an average point preva-
lence of DSM anxiety disorders and clinically relevant anxiety symptoms. In Chapter 3, 
a clinical model of anxiety in PD is proposed, implementing both non-PD and PD-spe-
cifi c risk factors and their relative contributions to the anxiety outcome. 
In Chapter 4, we explored the multidimensionality of the Hamilton Depression Rating 
Scale (HAMD), the most common used measure of depressive symptoms, by conduc-
ting an exploratory factor analysis.  Since education of depressed patients when star-
ting antidepressants greatly improves compliance, we explored in Chapter 5 diﬀ erential 
response patterns to treatment with venlafaxine or paroxetine in the aﬀ ective, somatic 
and cognitive domains of depressed PD patients. Second, we studied the timing of the 
placebo response during a 12-week study period.
In Chapter 6 we investigated the feasibility of a new method to determine non-motor 
symptoms in daily life in PD: the Experience Sampling Method (ESM). Th is method 
assesses motor symptoms, aﬀ ective states and contextual factors at random moments 
in the fl ow of daily life, using an application on a mobile device. ESM holds promises 
for future research to unravel the complex relationship between non-motor symptoms, 
like anxiety and depression, with motor symptoms and contextual infl uences. Finally, 
in Chapter 7 the most important fi ndings of this thesis are refl ected and the conceptual 
design of anxiety and depression in PD is discussed. 
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ABSTRACT
Objective: 
Prevalence rates of anxiety disorders in Parkinson’s disease vary widely, ranging from 6 
up to 55%. Th e aim of this systematic review was to calculate average point prevalence 
of anxiety disorders and clinically relevant anxiety symptoms in PD.
Methods: 
Using PubMed, we carried out a systematic literature search for studies reporting DSM 
defi ned anxiety disorders or clinically relevant anxiety symptoms assessed by an anxiety 
rating scale. 
Results: 
A total of 49 articles were included and assessed for quality, 45 fulfi lled the quality crite-
ria. Th e average point prevalence of anxiety disorders in PD was 31%, with non-episo-
dic anxiety being more prevalent than episodic anxiety. Generalized anxiety disorder was 
the most frequent in 14%, followed by social phobia (13.8%), anxiety NOS (13.3%) 
and specifi c phobia (13.0%). Panic disorder with or without phobia was present in 
6.8% of PD patients.  Th irty-one percent (31%) of patients fulfi lled criteria for current 
multiple anxiety disorders. Based on anxiety rating scale cutoﬀ  scores, clinically signifi -
cant anxiety symptoms were present in a weighted average of 25.7%.
Conclusion: 
Th is systematic review confi rms that anxiety, although often unrecognized, is very com-
mon and highlights the need for eﬃ  cient identifi cation of anxiety in PD.
Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder primarily characterized by mo-
tor symptoms; however non-motor symptoms such as anxiety and depression are com-
mon in PD. Anxiety disorders include generalized anxiety disorder (GAD), panic disor-
der, agoraphobia, obsessive-compulsive disorder (OCD), social or specifi c phobia and 
anxiety not otherwise specifi ed (NOS)(1). Th ey contribute to cognitive impairment, 
increased severity of motor symptoms such as on/oﬀ  fl uctuations or freezing episodes 
(2-4), and also have a negative impact on quality of life and self-perceived health status 
(5-7). 
Although anxiety syndromes are common in PD, they have not been extensively studied. 
Research on mood disorders in PD has predominantly focused on depressive disorders. 
Prevalence rates of anxiety in PD that are reported in the literature vary widely. Up to 
55% of PD patients experience substantial anxiety symptoms (8), and up to 40% have 
a circumscribed anxiety disorder as defi ned by the criteria of the Diagnostic and Sta-
tistical Manual (DSM) (9). Possible reasons for this variation include the nature of the 
population studied, the way the diagnosis is established, diﬀ erences in the number of 
ascertained DSM diagnoses and the statistical measures used. Against this background, 
this systematic review aims to calculate an average point prevalence of DSM anxiety 
disorders and clinically relevant anxiety symptoms in PD.
METHODS
Search strategy
A systematic review (Figure 1, PRISMA fl ow chart) of research-based literature catalo-
ged in PubMed, Medline and Cochrane library was performed. Th e entire time scale 
was used up to September 19th 2015. In order to include all existing literature on anxie-
ty in PD, we only used the key terms: “anxiety” in combination with “Parkinson*”. 
Articles with an abstract available and written in English, German, French or Dutch 
were screened.  Th e abstracts of these 1257 articles were read and studies reporting any 
anxiety disorder or anxiety level using a (validated) anxiety scale were subsequently read 
in full.  Studies reporting anxiety by using a global non-motor scale (such as non-mo-
tor symptoms scale, NMSS (10) or the Movement Disorder Society revised Unifi ed 
Parkinson Disease Rating Scale (MDS-UPDRS)(11)), reviews and studies with only 
DBS patients were excluded. All articles with potential reference to the prevalence of 
anxiety were assessed for eligibility. After reading these articles, another 58 articles were 
excluded because of the following reasons: there was no reference to the actual preva-
lence of anxiety (n=28), no cut-oﬀ  score on an anxiety rating scale was reported (n=8), 
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the population included only PD patients with dementia, psychosis or mood fl uctu-
ations (n=9). In addition, if, during the assessment it became clear that publications 
stemmed from the same databases (n=13), only one of these publications was included 
in the meta-analysis to prevent a disproportional infl uence of these the prevalence rates 
reported in these publications. If studies were indeed based on the exact same sample, 
we decided to include only the fi rst publication in the analysis. When studies based on 
the same sample had varying numbers of patients included (as is the case in cumulative 
databases), the study with the highest number of patients was included. Th e remaining 
49 studies were included in the qualitative synthesis. 
Figure 1. 
PRISMA ﬂ ow-chart
Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis.
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Quality assessment
With regard to the reported prevalences, the quality of the studies was assessed with 
epidemiological quality criteria. Th e modifi ed Quality Assessment of Diagnostic Ac-
curacy Studies (QUADAS) tool is a quality assessment adapted and modifi ed from Le-
boeuf-Yde et al. (12, 13), and previously used to determine the prevalence of pain in 
PD (14). Th e modifi ed QUADAS tool includes 10 criteria in which the reliability of 
the prevalence study is evaluated (Table 1). Th e score ranges from 0 to 19 points, with a 
cutoﬀ  level for methodological acceptability set at > 13 points, which is 75% of the total 
points that can be achieved. All articles were reviewed independently by 2 researchers 
(M.B., N.N.) and in case of discrepancies between the raters, consensus was achieved 
after discussion if possible, or a decision was made after reassessment by the last author 
(A.L.). Th e complete list of included studies with their item-by-item quality score is 
provided as supplementary information.
Table 1. 
Modiﬁ ed QUADAS tool: quality criteria for prevalence studies. 
A Th e fi nal sample should be representative of the target population
1 At least 1 of the following should apply for the study (2 points):
- An entire target population
- Randomly selected sample
- Sample stated to represent the target population
2 At least one of the following (2 points)
- Reasons for nonresponders described
- Nonresponders described
- Comparison of responders and nonresponders
- Comparison of sample and target population
3 Response rate ≥ 90% (2 points)
Response rate 70% to 90% (1 point)
Response rate ≤ 70% (0 points)
B Quality of data
4 Were the data primary from a prevalence study (2 points) or was it taken from a survey not specifi cally 
designed for that purpose (1 point)
5 Th e same mode of data collection should be used for all subjects  (2 points), if not: 1 point
6 - Th e data have been collected directly from the patient by means of a validated questionnaire/interview 
(3 points)
- No validated questionnaire/interview patients (2 points)
- Data have been collected from proxies or retrospectively from medical record (1 point).
C General description of the method and results should include:
7 Description of target population and setting where patients were found (2 points)
8 Description of stage of disease, sex, age (all 2 points, 1 or 2: 1 point)
9 Final sample size (1 point)
D Defi nition of anxiety prevalence
10 Prevalence recall periods should be stated (1 point)
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Data extraction and analyses
For studies assessing specifi c anxiety disorders, the prevalences were recorded in combi-
nation with the clinical setting and sample size. Two studies (15, 16) on anxiety disor-
ders only reported a total percentage of anxiety disorders. For these we contacted the 
fi rst author for information on the percentage of individual anxiety disorders. For one of 
these studies, this information could be obtained (15). For all studies using cutoﬀ  scores 
on anxiety rating scales, the prevalence percentage represents the presence of anxiety 
symptoms that was regarded as clinically relevant in these studies. Currently, there is no 
clear consensus about the best cut-oﬀ  scores on the anxiety rating scales (17-19). Au-
thors of the included studies chose cut-oﬀ  scores referencing to other articles or based on 
own experiences. Since cut-oﬀ  values vary across studies, we used for the sake of this re-
view the thresholds stated by the authors of the studies. Th e number of patients scoring 
above the threshold of an anxiety rating scale was taken as the prevalence of clinically 
relevant anxiety symptoms. Prevalence rates across studies were calculated as weighted 
means. Th e prevalence rate per study was multiplied by the corresponding sample size 
and divided by the total sample of all studies. 
RESULTS
Of a total of 49 studies, 27 focused on the prevalence of anxiety in PD as a primary 
objective. Other studies had other primary objectives but also reported the prevalence of 
anxiety in the study sample as a secondary outcome. Of the 49 studies included in the 
qualitative synthesis, 45 met the cutoﬀ  score of 14 points on the QUADAS tool (92%). 
Th e actual scores ranged from 12-19 points with a mean of 15.45  (see supplementary 
information). Only 5 out of the 45 studies were conducted before the year 2000, with 
more than half of the papers published in the last 5 years, which likely refl ects the 
increasing awareness of anxiety in PD in the last decade. Th irty-nine studies were in 
outpatient settings, often in movement disorder clinics, and 5 were population-based. 
One study included both inpatients and outpatients. Eighteen studies reported anxie-
ty disorders according to the DSM criteria and 27 reported clinically relevant anxiety 
symptoms assessed with an anxiety rating scale. Of the eighteen studies examining DSM 
defi ned anxiety disorders, one was a population study in the Netherlands (20). Four 
were multicenter studies (9, 21-23), of which 1 was conducted in China, 1 in the USA 
and 2 as well in the USA, Europe and Australia. Of the 13 single center studies, three 
included patients from the USA (24-26), 6 from Europe (15, 16, 27-30), 2 from South 
America (31, 32), 1 from Australia (7) and 1 from India (33). An overview of studies 
reporting the prevalence of anxiety disorders is illustrated in Table 2, and studies repor-
ting clinically relevant anxiety symptoms according to validated rating scales are shown 
in Table 3.
Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis.
27
C
ha
pt
er
 2
Chapter 2
28
Ta
bl
e 
2.
 
O
ve
rv
ie
w
 o
f s
tu
di
es
 re
po
rt
in
g 
th
e 
pr
ev
al
en
ce
 o
f a
nx
ie
ty
 d
is
or
de
rs
 in
 P
ar
ki
ns
on
’s 
di
se
as
e 
ac
co
rd
in
g 
to
 D
SM
 c
rit
er
ia
 (n
=1
8)
. 
St
ud
y
Sa
m
pl
e
Sa
m
pl
e 
si
ze
Q
ua
lit
y 
sc
or
e
Sc
al
e 
us
ed
Pa
ni
c 
di
so
rd
er
 
(t
ot
al
)
Pa
ni
c 
di
s-
or
de
r 
w
it
h 
ag
or
ap
ho
bi
a
Pa
ni
c 
di
so
r-
de
r 
w
it
ho
ut
 
ag
or
ap
ho
bi
a
A
go
ra
ph
ob
ia
 
(t
ot
al
)
G
A
D
So
ci
al
 
ph
ob
ia
Ph
ob
ia
 
ot
he
r
O
C
D
A
nx
-
ie
ty
 
N
O
S
A
nx
ie
ty
 
di
so
rd
er
 
(t
ot
al
)
2 
or
 m
or
e 
an
xi
et
y 
di
so
rd
er
s2
St
ei
n 
et
 a
l. 
(1
99
0)
O
ut
pa
tie
nt
 
cl
in
ic
24
17
D
SM
 II
I-
R
8.
3%
4.
2%
12
.5
%
37
.5
%
M
en
za
 e
t a
l. 
(1
99
3)
O
ut
pa
tie
nt
 
cl
in
ic
42
14
D
SM
 II
I-
R
11
.9
%
11
.9
%
2.
4%
2.
4%
28
.6
%
St
ar
ks
te
in
 e
t 
al
. (
19
93
)
O
ut
pa
tie
nt
 
cl
in
ic
40
16
D
SM
 II
I
52
.5
%
D
e 
R
ijk
 e
t a
l. 
(1
99
8)
Po
pu
la
tio
n
38
4
17
C
ID
I 
(D
SM
-II
I-R
)
2.
3%
4.
9%
2.
6%
11
.5
%
12
.2
%
0.
3%
24
.5
%
23
.7
%
N
ut
i e
t a
l. 
(2
00
4)
O
ut
pa
tie
nt
 
cl
in
ic
90
15
D
SM
 IV
30
.0
%
11
.1
%
5.
5%
46
.7
%
K
um
m
er
 e
t a
l. 
(2
00
8)
O
ut
pa
tie
nt
 
cl
in
ic
90
15
M
IN
I
6.
7%
31
.1
%
50
.0
%
13
.3
%
M
on
te
l e
t a
l. 
(2
00
9)
O
ut
- a
nd
 
in
pa
tie
nt
s
13
5
17
M
IN
I
25
%
10
.0
%
12
.0
%
3.
0%
34
.0
%
C
he
n 
et
 a
l. 
(2
01
0)
O
ut
pa
tie
nt
 
cl
in
ic
13
3
18
SC
ID
2.
3%
8.
3%
8.
3%
8.
3%
2.
3%
5.
3%
27
.1
%
Bo
llu
k 
et
 a
l. 
(2
01
0)
O
ut
pa
tie
nt
 
cl
in
ic
50
15
SC
ID
16
.0
%
D
iss
an
ay
ak
a 
et
 a
l. 
(2
01
0)
O
ut
pa
tie
nt
 
cl
in
ic
79
17
M
IN
I
7.
6%
7.
6%
7.
6%
15
.0
%
12
.7
%
1.
3%
25
.3
%
D
ia
s e
t a
l. 
(2
01
1)
O
ut
pa
tie
nt
 
cl
in
ic
30
19
M
IN
I
6.
7%
40
.0
%
43
.3
%
16
.7
%
3.
3%
Le
en
tje
ns
 e
t 
al
. (
20
11
)
O
ut
pa
tie
nt
 
cl
in
ic
34
2
14
M
IN
I
3.
9%
1.
8%
2.
1%
15
.5
%
20
.6
%
10
.0
%
11
.4
%
34
.5
%
 
34
.8
%
Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis.
29
C
ha
pt
er
 2
Po
nt
on
e 
et
 a
l. 
(2
01
1)
O
ut
pa
tie
nt
 
cl
in
ic
24
9
18
SC
ID
5.
2%
1.
6%
3.
6%
6.
8%
15
.7
%
0.
8%
22
%
41
.8
%
28
.8
%
So
lla
 e
t a
l. 
(2
01
1)
O
ut
pa
tie
nt
 
cl
in
ic
34
9
19
M
IN
I
25
.2
%
G
ul
te
ki
n 
et
 a
l. 
(2
01
4)
O
ut
pa
tie
nt
 
cl
in
ic
80
18
SC
ID
7.
5%
42
.5
%
42
.5
%
5.
0%
Le
en
tje
ns
 e
t 
al
. (
20
14
)
O
ut
pa
tie
nt
 
cl
in
ic
36
2
14
M
IN
I
3.
4%
1.
7%
1.
7%
10
.5
%
15
.2
%
9.
1%
27
.0
%
37
.0
%
R
ai
 e
t a
l. 
(2
01
5)
O
ut
pa
tie
nt
 
cl
in
ic
12
6
17
M
IN
I
35
.7
%
Pe
lli
ca
no
 e
t a
l. 
(2
01
5)
1
O
ut
pa
tie
nt
 
cl
in
ic
84
14
SC
ID
36
.9
%
A
bb
re
vi
at
io
ns
: G
A
D
, g
en
er
al
iz
ed
 a
nx
ie
ty
 d
is
or
de
r; 
O
C
D
, o
bs
es
si
ve
-c
om
pu
ls
iv
e 
di
so
rd
er
; a
nx
ie
ty
 N
O
S,
 a
nx
ie
ty
 n
ot
 o
th
er
w
is
e 
sp
ec
iﬁ 
ed
. 1
D
ru
g 
na
ïv
e 
2  P
er
ce
nt
ag
e 
of
 p
at
ie
nt
s d
ia
gn
o-
se
d 
w
ith
 a
nx
ie
ty
.
Chapter 2
30
Table 3. 
Overview of studies reporting clinically relevant anxiety symptoms in Parkinson’s disease according to validated 
rating scales (n=27).
Study Sample Sample size Quality 
score
Scale used Cut-oﬀ  
score used
Clinically 
relevant anxiety 
symptoms
Marinu et al. (2002) Outpatient 
clinic 177 16 HADS ≥11 19.8%
Carod-Artal et al. 
(2007)
Outpatient 
clinic 144 14 HADS ≥11 23.6%
Mondolo et al. 
(2007)
Outpatient 
clinic 46 14 HADS ≥8 10.8%
Carod-Artal et al. 
(2008)
Outpatient 
clinic 115 14 HADS ≥11 30.4%
McKinley et al. 
(2008)
Outpatient 
clinic 42 15 HADS ≥8 16%
Havlikova et al. 
(2008)
Outpatient 
clinic 150 14 HADS ≥11 30.6%
Kulisevsky et al. 
(2008)
Outpatient 
clinic 1351 19 HADS ≥11 20.8%
Rodriquez-
Blastez et al. (2009)
Outpatient 
clinic 387 14 HADS ≥11 22%
Negres-Pages et al. 
(2010)
Population
422 17 HADS ≥11 (≥8) 27% (51%)
Hu et al. (2011) Population
197 14 HADS ≥11 32.0%
Brown et al. (2011) Outpatient 
clinic 513 16 HADS ≥11 22%
Ozdilek et al. (2012) Outpatient 
clinic 50 14 HADS ≥10 18%
Quelhas et al. (2014) Outpatient 
clinic 33 14 HADS ≥11 (≥8) 18.2% (54.5%)
Fereshtehnejad et al. 
(2015)
Outpatient 
clinic 140 14 HADS ≥8 38.9%
Borek et al. (2006) Outpatient 
clinic 120 16 HARS ≥14 23.2%
Stefanova et al. 
(2013)
Outpatient 
clinic 360 19 HARS ≥11 37.8%
Jiang et al. (2015) Outpatient 
clinic 99 14 HARS >11 25.3%
Wu et al. (2015) Outpatient 
clinic 301 15 HARS >14 10.6%
Schulman et al. 
(2001)
Outpatient 
clinic 101 16 BAI ≥10 39%
Rutten et al. (2015) Outpatient 
clinic 294 16 BAI >12 45%
Yamanashi et al. 
(2013)
Outpatient 
clinic 117 15 STAI 41(m) 42 (f ) 55%
Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis.
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(2015)1
Outpatient 
clinic 423 15 STAI >39 24.6% 
Siri et al. (2010) Population 486 15 SCL-90 >1 46%
Bugalho et al. (2012) Outpatient clinic 36 15 SCL-90-R >1 28%
Henderson et al. 
(1992)
Outpatient 
clinic 164 16 Zung >49 15%
Baig et al. (2015) Outpatient clinic 769 17
Leeds 
anxiety score >7 17.3%
Aarsland et al. 
(2009)1 Population 175 16 NPI ≥4 6.9%
1 Drug naive
Overall, a weighted mean of 31% (range 24.5–46.7%) in a total of 2399 patients expe-
rienced an anxiety disorder, with GAD as the most frequent disorder (14.1%), followed 
by social phobia (13.8%) and clinically relevant anxiety not meeting criteria for any 
specifi c anxiety diagnoses (anxiety NOS, 13.3%) (Table 4). Th irty-one percent (31.1%) 
of patients fulfi lled criteria for current multiple anxiety disorders, having two diﬀ erent 
or more anxiety disorders at one time point. Of the studies reporting a total prevalence 
of anxiety disorders, we compared the weighted prevalence of anxiety disorders in mul-
ticenter versus single center studies, which was 32.8% in multicenter (1086 patients (9, 
21-23)) versus 31.5% in single center studies (929 patients (7, 15, 16, 24, 26, 29, 30, 
33)). Studies conducted in the USA, Europe and one in India found a higher overall 
prevalence of anxiety disorders compared to the multicenter study conducted in China 
(21) (Table 2). Based on anxiety rating scale cutoﬀ  scores, clinically signifi cant anxiety 
symptoms were present in a weighted average of 25.7% (range 6.9% to 55%). 
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Table 4. 
Weighted prevalences of anxiety disorders in Parkinson disease patients 
Anxiety disorder Number 
of studies
Total no. PD 
patients
Range Weighted preva-
lence
Any anxiety disorder 13 2399 24.5 – 46.7 31.0%
- Generalized anxiety disorder 14 2080 2.6 – 52.5 14.1%
- Panic disorder 13 2040 2.3 – 30.0 6.8%
- Agoraphobia 7 1684 1.6 – 15.5 8.6%
- Social phobia 11 1823 6.8 – 50.0 13.8%
- Phobia other 4 705 2.4 – 16.7 13.0%
- OCD 9 1270 0.3 – 13.3 2.6%
- Anxiety NOS 4 766 2.4 – 22.0 13.3%
Two or more comorbid anxiety disorders* 4 1337 23.7 – 37.0 31.1%
Clinically relevant anxiety symptoms accord-
ing to scale
27 7212 6.9 – 55.0 25.7%
*Percentage of patients diagnosed with anxiety
DISCUSSION
Th is is the fi rst systematic review examining the prevalence of anxiety disorders and 
anxiety symptoms in PD. It shows that the average point prevalence of anxiety disorders 
in PD is 31%. Th is is a substantial percentage that exceeds the average point prevalence 
of depressive disorders in PD (17%) (34). Non-episodic anxiety was more prevalent 
than episodic anxiety with generalized anxiety disorder as the most frequent diagnosis in 
14.1% of PD patients, and was followed by social phobia in 13.8% and panic disorder 
with or without agoraphobia in 6.8%.  Approximately one third of patients diagnosed 
with anxiety experienced multiple anxiety disorders, which makes the construct validity 
of the current DSM classifi cation of anxiety questionable, at least in PD patients.  Nota-
bly, anxiety NOS had a weighted prevalence similar to GAD and social phobia (13.3%), 
and this is a category often used to describe signifi cant anxiety that do not neatly meet 
criteria for a standard DSM disorder. 
Th e weighted average of clinically relevant anxiety symptoms assessed by a rating scale 
was lower (25.7%) than the weighted average of DSM defi ned anxiety disorders (31%). 
It is well known that most anxiety rating scales are inappropriate to diagnose anxiety 
disorders in PD (18, 19). A possible explanation for the lower prevalence of anxiety 
when anxiety rating scales are used, is the fact that some anxiety disorders take place in 
special situations, such as social phobia, and the commonly used anxiety rating scales do 
not contain items that explore such situations. Second, the inclusion of anxiety NOS 
in the prevalence estimates of anxiety disorders may also explain the discrepancy bet-
Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis.
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ween the prevalence fi nding of DSM anxiety disorders and rating scale anxiety. Th is is 
because rating scales may not capture symptoms of anxiety disorder NOS, which may 
be a predominant construct of PD-specifi c anxiety symptoms (1, 35, 36).  Furthermore, 
authors have used diﬀ erent cut-oﬀ  scores, and the focus of specifi c anxiety symptoms 
may diﬀ er between rating scales. For example, the BAI focuses mainly on symptoms of 
panic, while the HARS predominantly consists of items assessing generalized anxiety. 
Th e positive predictive values of these popular scales are suggested to be low in PD, and 
consequently may contribute to a poor diagnostic accuracy (18). Th e recently designed 
Parkinson Anxiety Scale, could possibly overcome some of these problems (23).
Comparing anxiety in PD and the general population or other illnesses
Th e weighted prevalence of anxiety disorders in PD is much higher than those reported 
in the general population or other medically ill patients, without PD (24, 37). A large 
community survey from the World Health Organization found a 12-month prevalence 
of 8.3% of any anxiety disorder. In addition, an extensive review of epidemiological 
surveys on anxiety disorders in the general population found 12-month prevalences of 
panic disorder range of 0.7-3.1%, GAD 0.2-4.3% and social phobia of 0.6-7.9% (38). 
GAD and social or specifi c phobias seem to be the most common anxiety disorders in 
PD and panic disorder, agoraphobia and OCD the least frequent. Th ese observations 
are in line with studies focusing on anxiety in the general population (39, 40). About 
one third of patients had two or more comorbid anxiety disorders, and having multiple 
anxiety disorders is associated with greater morbidity (41). GAD with another non-epi-
sodic anxiety disorder like social phobia or agoraphobia seems to be the most frequent 
comorbid disorders in PD (22), and in the general population (42, 43). In addition, 
there is a particular high correlation between major depression and GAD in general 
(44). Depression is common in PD and has a clear symptom overlap with GAD, which 
may explain the high prevalence of GAD in general and in PD. Although investigating 
the lifetime prevalence of anxiety disorders in PD was not our primary objective, we 
noted two studies reporting a lifetime prevalence of anxiety disorders in PD. Pontone et 
al. (45) reported a lifetime prevalence of anxiety disorders of 49% in 127 patients, with 
specifi c phobia as the most frequent disorder. Lauterbach et al. (3) reported 25% of 28 
patients with a life time panic disorder, none with GAD and 32% with anxiety NOS. 
Th e lifetime prevalence of anxiety in PD thus also seem to be higher than in the general 
population, in which prevalence rates range from 15-34% (38). 
Variation of reported prevalences
Th ere is a wide range of reported prevalence across studies included in this review, which 
most likely is attributable to methodological diﬀ erences. Th ree studies in the early ni-
neties used DSM-III criteria, whereas later ones used the DSM-IV criteria. No studies 
using DSM-5 criteria in PD have yet been published. Secondly, in the general popula-
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tion there are some slight diﬀ erences between the MINI and the SCID interview; the 
MINI being slightly more over inclusive in making the diagnosis hence possible leading 
to a higher prevalence rate (46). Th irdly, individual diﬀ erences in the extent of history 
taking and the conscientiousness of the assessor may aﬀ ect the decision to code the 
patient complaints as one single or as two disorders and interpretation of MINI formu-
lations or DSM criteria may be diﬀ erent between studies. For example, some researchers 
used hierarchal DSM criteria and ruled out GAD if another current anxiety disorder 
was diagnosed, whereas others included secondary GAD as a disorder when evaluating 
frequency. We decided to include the latter prevalence in our review when both were 
reported (7).  In addition, using an “inclusive” approach, where overlapping symptoms 
of anxiety and PD is taken together in the diagnosis regardless of the causal attribution, 
when applying diagnostic criteria tend to give a higher prevalence than an “exclusive” 
approach (47). Furthermore, diﬀ erences in the characteristics of the study samples could 
also infl uence the reported prevalence. Anxiety is more common in western developed 
countries; for example anxiety is more common in the United States compared with 
China, which is in line with our fi ndings (48). Also, some studies did not include the 
whole spectrum of anxiety disorders, such as anxiety NOS or phobias other than social 
phobia, but did report a total percentage of anxiety disorders (7, 15, 20, 23, 26, 29), 
which could have led to an underestimation of the true prevalence of anxiety disorders 
in PD. Last, although some described diﬀ erences between multi- and single center trials 
(49), we found no diﬀ erence in the prevalence of the total number of anxiety disorders. 
A diﬀ erent classifi cation, such as the one recently proposed by Starkstein et al. could aid 
in diﬀ erentiating clinical profi les of anxiety in PD. Th is study identifi ed three diﬀ erent 
presentations of anxiety, namely episodic anxiety which is not associated with depressive 
symptoms, persistent anxiety with depression, or both persistent and episodic anxiety 
with depression. Th ese clinical phenotypes may correspond better to the anxiety syndro-
mes encountered in clinical practice than those listed in the DSM classifi cations (50).
Th ere are a number of limitations of this review. Although we attempted to identify all 
suitable publications and exclude publications stemming from the same database, we 
may have missed some of these overlapping publications. Secondly, although all articles 
were assessed by quality criteria, the inclusion criteria chosen was subjective to authors. 
Th ird, we cannot completely rule out a possible infl uence of recruitment bias. Most of 
the studies were conducted at specialized movement disorder clinics, where they may 
encounter more complex patients with a higher prevalence of anxiety disorders. Fourth, 
92% of studies met QUADAS criteria, which is much higher than other systematic 
reviews in PD (14) and other chronic diseases (12, 51). Having a search strategy in-
corporating some of the quality criteria may explain this high percentage. Lastly, since 
this review depends on the quality of the studies included, we cannot rule out possible 
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infl uences of pharmacological treatment of anxiety on the reported prevalences. For 
example, patients successfully treated with anxiolytics may not be recognized, and this 
may lead to an under-reporting of anxiety in this review. 
However, taking all these considerations into account, we calculated weighted averages 
of prevalence reported in available studies with the intention to provide a reliable esti-
mate of the frequency of anxiety disorders in PD patients. Although anxiety in PD was 
relatively neglected for a long time, it receives more and more intention in the last 10-15 
years. However, studies have indicated that still over half of clinically signifi cant anxiety 
cases are not recognized by clinicians, and therefore anxiety is undertreated both in PD 
and in the general elderly population (35, 52-54). By demonstrating a high weighted 
point prevalence rate for anxiety disorders in PD (31%), the present systematic review 
suggests the need for eﬃ  cient identifi cation of anxiety in PD , which occur at a much 
higher average prevalence than depressive disorders in PD (17%). Given this high preva-
lence of anxiety, pharmacological and non-pharmacological treatment of anxiety needs 
to be further studied and optimized for PD patients (34, 55).
CONCLUSION
In this review we aimed to determine the prevalence of anxiety in patients with PD. 
Th e average prevalence of anxiety disorder was 31%, with GAD as the most frequent in 
14.1% followed by social phobia (13.8%), anxiety disorder NOS (13.3%) and specifi c 
phobia (13.0%). About one third of diagnosed patients had two or more anxiety disor-
ders. Th is study confi rms that anxiety, although often unrecognized, is very common 
in PD.
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SUPPLEMENTARY FILES
Table S1. 
Study quality according to the modiﬁ ed QUADAS tool.
Article A1 A2 A3 B4 B5 B6 C7 C8 C9 D10 Total
Aarsland et al. 2009 2 2 1 2 2 1 2 2 1 1 16
Bolluk et al. 2010 2 0 0 2 2 3 2 2 1 1 15
Brown et al. 2011 2 2 0 1 2 3 2 2 1 1 16
Bugalho et al. 2012 2 0 0 2 2 3 2 2 1 1 15
Carod-Artal et al. 2007 2 0 0 1 2 3 2 2 1 1 14
Carod-Artal et al. 2008 2 0 0 1 2 3 2 2 1 1 14
De Rijk et al. 1998 2 2 0 2 2 3 2 2 1 1 17
Dias et al. 2011 2 2 2 2 2 3 2 2 1 1 19
Dissanayaka et al. 2010 2 2 0 2 2 3 2 2 1 1 17
Gultekin et al. 2014 2 2 2 2 2 3 2 1 1 1 18
Havlikova et al. 2008 2 0 0 1 2 3 2 2 1 1 14
Hu et al. 2011 2 0 0 1 2 3 2 2 1 1 14
Kulisevsky et al. 2008 2 2 2 2 2 3 2 2 1 1 19
Kummer et al. 2008 2 0 0 2 2 3 2 2 1 1 15
Leentjens et al. 2011 2 0 0 1 2 3 2 2 1 1 14
Leroi et al. 2012 2 0 0 2 2 1 2 2 1 1 13
Marinus et al. 2002 2 0 1 2 2 3 2 2 1 1 16
McKinlay et al. 2008 2 2 0 1 1 3 2 2 1 1 15
Menza et al. 1993 2 0 0 1 2 3 2 2 1 1 14
Monastero et al. 2013 2 0 0 1 2 1 2 2 1 1 12
Mondolo et al. 1997 2 0 0 1 2 3 2 2 1 1 14
Montel et al. 2009 2 2 1 1 2 3 2 2 1 1 17
Negre-Pages et al. 2009 2 0 2 2 2 3 2 2 1 1 17
Nuti et al. 2004 2 0 0 2 2 3 2 2 1 1 15
Pontone et al. 2011 2 2 2 1 2 3 2 2 1 1 18
Quelhas et al. 2009 2 0 0 1 2 3 2 2 1 1 14
Qureshi et al. 2010 0 0 2 2 2 1 2 1 1 1 12
Rodriguez-Blazquez et al. 2009 2 0 0 1 2 3 2 2 1 1 14
Schulman et al. 2001 2 0 2 1 2 3 2 2 1 1 16
Siri et al. 2010 2 0 0 2 2 3 2 2 1 1 15
Solla et al. 2011 2 2 2 2 2 3 2 2 1 1 19
Stefanova et al. 2013 2 2 2 2 2 3 2 2 1 1 19
Yamanishi et al. 2013 2 0 0 2 2 3 2 2 1 1 15
Starkstein et al. 19«3 2 0 2 2 2 3 2 1 1 1 16
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Ozdilek et al. 2012 2 0 0 1 2 3 2 2 1 1 14
Chen et al. 2010 2 2 1 2 2 3 2 2 1 1 18
Stein et al. 1990 2 0 2 2 2 3 2 2 1 1 17
Henderson et al. 1992 2 2 0 2 2 3 2 1 1 1 16
Borek et al. 2006 2 2 0 1 2 3 2 2 1 1 16
Zarowitz et al. 2013 0 0 2 2 2 1 2 1 1 1 12
Rai et al. 2015 2 0 2 2 2 3 2 2 1 1 17
Baig et al. 2015 2 2 0 2 2 3 2 2 1 1 17
Fereshtehnejad et al. 2015 2 0 0 1 2 3 2 1 1 1 14
Jiang et al. 2015 2 0 0 1 2 3 2 2 1 1 14
Pellicano et al. 2015 2 0 0 1 2 3 2 2 1 1 14
Rutten et al. 2015 2 2 0 1 2 3 2 2 1 1 16
Weintraub et al. 2015 2 0 0 2 2 3 2 2 1 1 15
Wu et al. 2015 2 0 0 2 2 3 2 2 1 1 15
Leentjens et al 2014 2 0 0 1 2 3 2 2 1 1 14
Broen MP, Köhler S, Moonen AJ, Kuijf ML, Dujardin K, Marsh L, 
Richard IH, Starkstein SE, Martinez-Martin P, Leentjens AF.
Mov Disord. 2016 Mar;31(3):310-6. 
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ABSTRACT
Objective: 
To construct a model for anxiety in Parkinson’s disease (PD) and to compare the relative 
contributions of PD-specifi c and nonspecifi c general population risk factors for anxiety 
in this model. 
Methods: 
Structural equation modelling of associations of risk factors with the anxiety outcome 
using a cross-sectional dataset of 342 patients with PD. 
Results: 
A model with acceptable to good fi t was generated that explained 65% of the variance 
in anxiety scores. A previous history of depression and the severity of the depressive 
symptoms scored on the Hamilton Depression Rating Scale were the only nonspeci-
fi c variables with a direct eﬀ ect on anxiety. Th e presence of motor fl uctuations and 
disease-related decline in activities of daily living were PD-specifi c markers of anxiety. 
Nonspecifi c risk factors had a greater infl uence in the model than PD-specifi c risk fac-
tors. Standardized regression coeﬃ  cients suggested that the Hamilton Depression Ra-
ting Scale- score was the most important contributor to the variation in anxiety. A post 
hoc analysis showed that the eﬀ ects of the following variables on anxiety levels were fully 
mediated via depression: sex, family history of depression, previous history of anxiety, 
cognitive status, diﬃ  culties in non-disease-specifi c activities of daily living and severity 
of motor signs.
Conclusion: 
In this cross-sectional study, we showed that nonspecifi c general population risk factors 
are more important markers for anxiety than PD-specifi c risk factors. Depression was 
the most prominent marker. PD-specifi c markers for anxiety appear to be more situa-
tional, and related to 'oﬀ ' periods and disease-specifi c disturbances of activities of daily 
living.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disease in which non-motor symptoms, 
such as anxiety, depression and apathy are common and an important determinant for 
quality of life (1). Anxiety disorders include, amongst others, generalized anxiety, panic 
attacks and social phobia. Th ese disorders contribute to the severity of motor signs, 
motor complications such as dyskinesias and on/oﬀ  fl uctuations, gait disturbances in-
cluding freezing of gait and cognitive impairment (2-4). As for the general population, 
anxiety disorders in PD develop in the context of multiple interacting risk and protec-
tive factors. Th ese factors may or may not be specifi c to PD itself. In the general popu-
lation, longitudinal studies have shown that risk factors for anxiety include female sex 
and comorbid physical disease. Moreover, personal circumstances such as personality 
traits, coping, and stressful life events also play a role (5-7). In cross-sectional studies, 
some PD specifi c risk factors for anxiety have been identifi ed, including longer disease 
duration, presence of motor fl uctuations and levodopa use (3, 8, 9). Only a few studies 
have investigated the role of general risk factors for anxiety in PD. 
For depression, we recently showed that the more prominent markers for depression are 
non-PD specifi c, in contrast to PD-specifi c factors (10). Th e objective of this study was 
to construct and test a similar model of factors related to anxiety in PD, and to compare 
the relative contributions of PD-specifi c and nonspecifi c general population markers to 
the anxiety outcome.
METHODS
Data from the database of a cross-sectional multicenter study on anxiety disorders in 
PD conducted in 2008 and 2009 were used, the results of which have been described 
earlier (9, 11).
Population
Th e database includes 342 patients with idiopathic PD, diagnosed according to the 
Queen Square Brain Bank criteria (12). Patients were recruited from consecutive refer-
rals to movement disorders clinics, neurology clinics and psychiatry clinics of 6 centers 
in the United States, Europe, and Australia. All subjects underwent a comprehensive 
neurologic and neuropsychiatric assessment. Patients with clinically relevant cognitive 
impairment were excluded, which was operationalized as a Mini-Mental State Exami-
nation (MMSE) score below 26 following the recommendation of a Movement Disor-
der Society (MDS) Task Force (13, 14). In addition, patients with neurodegenerative 
disorders other than PD and patients who had undergone deep brain stimulation were 
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excluded. All types of medication, including neurologic and psychotropic agents, were 
allowed. 
Standard protocol approvals, registrations, and patient consents
Th e study was approved by the local Medical Ethics Committee at each participating 
institution. Participants gave written informed consent before inclusion in the study. 
Assessment 
In accordance with MDS Task Force recommendations, subjects who experienced mo-
tor fl uctuations were examined only during “on” states and rated using an “inclusive” 
approach, meaning that the symptoms were scored as observed or reported irrespective 
of their assumed etiology (15). Demographic and disease-related variables were assessed 
during a clinical interview. Disease stage was rated with the Hoehn &Yahr staging sys-
tem (16) and motor function, disease-related decline in activities of daily living (ADL) 
or complications of therapy with the Unifi ed Parkinson’s Disease Rating Scale (UPDRS, 
section II-IV) (17). Cognitive functioning and instrumental ADL were assessed with 
the MMSE and Lawton Instrumental ADL (IADL) scale, respectively (14, 18). Anxiety 
was quantifi ed with the clinician-rated Hamilton Anxiety Rating Scale (HARS) (19) 
and depression with the 17-item Hamilton Depression Rating Scale (HAMD) (20). 
Th e presence of anxiety disorders and depressive disorders according to the criteria of 
the 4th edition of the Diagnostic and Statistical Manual (DSM IV) were determined 
using the Mini International Neuropsychiatric Inventory (MINI), which is a structured 
interview for DSM-IV disorders, in particular the sections for anxiety (D, E, F, H) and 
depression (A,B) (21).
Statistical analysis
Th e total score on the HARS was chosen as outcome measure. Th is scale is particularly 
sensitive for symptoms of generalized anxiety disorder, the most prevalent anxiety disor-
der in PD(9).  Structural equation modeling (SEM) was performed in Mplus 7 (Muthén 
& Muthén, Los Angeles, CA) with the aim of identifying the most parsimonious model 
(taking into account model fi t and number of included parameters and model com-
plexity) that still accounted for a substantial part of the variance in the total score on 
the HARS. Variables were chosen on the basis of their known contribution to anxiety 
from the available literature. To discover collinearity between potential variables, an 
exploratory correlation analysis was performed. If the Spearman correlation coeﬃ  cient 
“r” between 2 potential parameters was both signifi cant (p< 0.005 after correction for 
multiple testing) and >0.40, a decision was made to include only one of these parame-
ters in the model, based on clinical relevance. An exception was made for the HAMD 
score. Although this score showed a relatively strong and signifi cant correlation with the 
HARS outcome, it was decided to keep this variable in the model, in order to be able 
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to identify its potential contribution to the anxiety model. Persistent anxiety in PD is 
almost invariably associated with depression (22).
An initial theoretic path model was constructed with the remaining parameters (mo-
del 1). Because the path model included continuous, binary, and ordered categorical 
variables, a mean- and variances- corrected weighted least-squares estimator was used. 
All parameters were evaluated in a simultaneous fashion. Model 1 included direct and 
indirect paths of the variables hypothesized to infl uence the anxiety outcome in order 
to test putative eﬀ ect mediation. Model fi t was primarily assessed by inspecting the root 
mean square error of approximation (RMSEA) and the Comparative Fit Index (CFI). 
For the RMSEA, scores ≤0.05 indicate good fi t, and scores ≤0.08 indicate acceptable 
fi t. Th e CFI ranges from 0 to 1 with scores ≥0.95 indicating good fi t and scores ≥0.90 
indicating acceptable fi t (23). Because the χ2 test is known to become positively biased 
with increasing sample size, this measure was not used to assess model fi t (23). Based on 
model fi t, the model was re-specifi ed. First, paths that did not contribute substantially 
(p> 0.10) to the model were removed manually in a backward 1-to-1 fashion, starting 
with the path with the highest p value, resulting in a second model (model 2). Next, 
modifi cation indices (MIs) were inspected to explore whether the model could be im-
proved by specifying additional paths among the remaining variables. Additional paths 
(e.g., mediation paths or correlations) were included based on the MIs and substantive 
interpretation (model 3). 
In a last step, we examined the contribution of PD-specifi c versus PD-nonspecifi c vari-
ables to the anxiety outcome. Two continuous latent variables (factors) were generated 
and regressed on anxiety. Th eir standardized regression coeﬃ  cients were compared using 
a Wald test. To have both factors on the same scale, their factors variances were fi xed to 1.
RESULTS
Sample characteristics
Th e demographic and disease characteristics of the included sample are listed in Table 
1(9, 11). Th e study population comprised 207 men and 134 women with an average 
age of 64.8 years (SD 9.2 years). Based on the MINI, 70 participants (21%) met the 
diagnostic criteria for a generalized anxiety disorder (GAD), 53 (16%) for agoraphobia 
without panic disorder, 13 (4%) for panic disorder and 34 participants (10%) met the 
diagnostic criteria for social phobia. Th irty-four percent of patients met the DSM-IV 
criteria for at least one anxiety disorder.
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Table 1. 
Demographic and disease characteristics of the sample (n = 341).
Variable Percentage Mean (SD) or median (range)
Female sex 39
Age 64.8 (9.2)
Duration of PD 8.3 (5.6)
UPDRS section 2 (ADL) 11.6 (6.8)
UPDRS section 3 (motor) 26.4 (12.4)
UPDRS section 4 (complications) 3.5 (3.5)
Hoehn & Yahr stage 2 (1-5)
On/oﬀ  fl uctuations 52
Generalized anxiety disorder 20.5
Panic disorder 3.9
Agoraphobia without panic disorder 15.5
Social phobia 10.0
Major depression 14.1
Dysthymia 5.6
Previous history depression 46.1
Previous history anxiety disorder 31.9
Family history depression 33.4
Family history anxiety disorder 19.4
Family history of PD 19.7
HAMD score (SD; range) 7.7 (5.9; 0-32)
HARS score (SD; range) 11.3 (8.5;0-50)
IADL score 7 (1.5)
MMSE score 28.5 (1.7)
Use of levodopa 85.3
Use of dopamine-agonist 61.6
Use of antipsychotic 3.8
PD = Parkinson's disease; UPDRS = Uniﬁ ed Parkinson's Disease Rating Scale; ADL = Activities of Daily Living; HAMD 
= Hamilton Depression Rating Scale; HARS = Hamilton Anxiety Rating Scale; IADL = Lawton's Instrumental Activi-
ties of Daily Living scale; MMSE = Mini Mental State Examination.
Results of the exploratory correlation analysis between variables that may be included in 
the regression analysis are shown in table e-1 (supplementary data). Based on the corre-
lation, disease stage (Hoehn & Yahr classifi cation) was excluded from the model because 
of a moderate strong correlation with UPDRS sections II, III and IADL (r = 0.55, r = 
0.56 and r = -0.48, respectively; all p<0.01). Separate parameters for the presence of 
motor fl uctuations and dyskinesias were included in the model.  It was decided to keep 
both the UPDRS section II (PD-specifi c ADL) and the score on the Lawton IADL scale 
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in the model, despite moderate correlation (r = -0.52, p <0.01). Th is was done because 
the UPDRS section II scores PD-related physical ADLs, whereas the IADL Scale can 
be considered a more general measure of independent functioning. It was also decided 
to keep the UPDRS section II score in the model despite its moderate correlation with 
UPDRS section III (r = 0.64, p<0.01). 
Th e initial theoretical model is shown in fi gure 1 and specifi ed in table e-2 (supplemen-
tary data). Nonspecifi c parameters included in this model were sex, age, previous history 
of anxiety, previous history of depression, family history of anxiety, family history of 
depression, depression score (HAMD total score), instrumental ADL function (IADL 
total score), and cognitive status (MMSE total score). PD-specifi c parameters in the 
model were disease duration, motor symptom severity (UPDRS section III total score), 
disease-specifi c ADL (UPDRS section II total score), presence of motor fl uctuations 
(based on UPDRS section IV), use of levodopa, and use of a dopamine agonist. Howe-
ver, because this model showed a poor fi t (RMSEA = 0.134, 90% CI = 0.125-0.144; 
CFI 0.600), it was rejected and exploratory SEM analyses were started.  
Figure 1.
Inital model of anxiety in PD (model 1)
Legend: ADL = activities of daily living; FH = family history; HAMD = Hamilton Depression Rating Scale; IADL = 
Instrumental Activities of Daily Living; MMSE = Mini-Mental State Examination; PD = Parkinson disease; UPDRS = 
Uniﬁ ed Parkinson’s Disease Rating Scale. 
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In a fi rst revision, paths that did not contribute signifi cantly to the model were deleted 
in a one-by-one fashion. Th is resulted in deletion of 11 of the 16 variables: sex, history 
of anxiety, family history of anxiety, family history of depression, age, instrumental ADL 
score, cognitive status, motor symptom severity, levodopa use, dopamine agonist use, 
and presence of dyskinesia. Th is second, simpler model (model 2) still showed inadequa-
te fi t (RMSEA 0.210, 90% CI = 0.182-0.239; CFI 0.846). A second revision (model 3), 
which allowed for correlated residuals among variables and extra paths as suggested by 
MI, resulted in a third model with acceptable to good fi t (RMSEA = 0.076, 90% CI = 
0.028-0.127; CFI 0.992). Th is fi nal model is shown in fi gure 2 and specifi ed in table 2. 
It explains 65.2% of the observed variance in the HARS outcome. 
Table 2. 
Standardized regression coefﬁ cients for the ﬁ nal model including 5 variables showing direct or indirect effects on 
anxiety (model 3). 
Parameter Dependent variable B SE β z Statistic p
Direct eﬀ ect on HARS score:
HAMD score HARS score 1.047 0.038 0.729 27.588 0.000
History depression HARS score 1.676 0.584 0.099 2.870 0.004
Motor fl uctuations HARS score 0.922 0.299 0.120 3.078 0.002
UPDRS II (ADL) HARS score 0.165 0.043 0.133 3.854 0.000
Indirect eﬀ ect on HARS score mediated through other variable:
HAMD score through 
UPDRS II (ADL)
HARS score 0.042 0.014 0029 2.97 0.003
Motor fl uctuations 
through UPDRS II 
(ADL)
HARS score -0.424 0.140 -0.055 -3.02 0.002
Disease duration 
through UPDRS II 
(ADL)
HARS score 0.086 0.027 0.057 3.241 0.001
Disease duration 
through motor fl uctu-
ations
HARS score 0.077 0.028 0.051 2.716 0.007*
Disease duration 
through motor fl uctu-
ations and UPDRS II 
(ADL)
HARS score -0.035 0.013 -0.023 -2.709 0.007*
Abbreviations: HAMD = Hamilton Depression Rating Scale; HARS = Hamilton Anxiety Rating Scale; UPDRS = 
Uniﬁ ed Parkinson's Disease Rating Scale; ADL = Activities of Daily Living; SE = standard error. 
* Path would become non-signiﬁ cant if Bonferroni-corrected (4 direct+5 indirect paths tested: αBonferroni = 0.05/9 = 
0.0055). Please note that paths are likely correlated and thus Bonferroni is overly conservative.
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Figure 2.
Final (third) model after removal of non-signiﬁ cant paths ands specifying additional indirect paths.
Legend: UPDRS = Uniﬁ ed Parkinson’s Disease Rating Scale; ADL= Activities of Daily Living. 
Standardized regression coeﬃ  cients suggested that HAMD depression scores contribu-
ted most to variation in HARS outcome (β=0.729, p <0.01), with relatively modest di-
rect eﬀ ects for history of depression, motor fl uctuations and disease-related impairment 
in ADL. Longer disease duration had a signifi cant indirect eﬀ ect only via its positive 
association with presence of motor fl uctuations and PD-specifi c ADL. To compare the 
relative contribution of PD-specifi c and nonspecifi c factors, we factorized depression 
and history of depression on one factor (PD-nonspecifi c) and disease duration, motor 
fl uctuations and PD-specifi c ADL on another factor (PD-specifi c). Th is showed that the 
eﬀ ects of both factors diﬀ ered (Wald = 46.40, df=1, p<.001), with the PD-nonspecifi c 
being signifi cantly associated with anxiety scores (β=0.913, p<.001) while the PD-spe-
cifi c factor was not (β=0.060, p=.376).
Given the very strong contribution of HAMD depression scores in model 3, we conduc-
ted an exploratory post-hoc analysis to test whether depression explained or mediated 
the eﬀ ect of the variables specifi ed in the initial model 1. We thus repeated the analytic 
approach from step 1 to step 3 as described above but removed the variable depression 
score from the model. Th e resulting post-hoc model, after removal of non-signifi cant 
paths and specifi cation of additional paths based on MI again, had poor fi t (RMSEA = 
0.112, 90% CI = 0.095-0.130); CFI 0.699), but was much more elaborate than model 
3, which included depression. We then added the depression variable in this post hoc 
model to see which variables infl uenced the HARS score through the depression score. 
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Th is resulted in a second post hoc model (shown in fi gure 3 and specifi ed in table e-3), 
which had an acceptable fi t (RMSEA = 0.076, 90% CI = 0.059-0.093; CFI 0.868) and 
explained 68.9% of the observed variance in the HARS outcome. 
Figure 3.
Model of anxiety in PD showing indirect effect mediated thougt depression (Second post-hoc model)
Legend: ADL = activities of daily living; FH = family history; HAMD = Hamilton Depression Rating Scale; IADL = 
Instrumental Activities of Daily Living; MMSE = Mini-Mental State Examination; PD = Parkinson disease; UPDRS = 
Uniﬁ ed Parkinson’s Disease Rating Scale.
Only previous history of depression, motor fl uctuations, and PD-specifi c ADLs had direct 
eﬀ ects on HARS outcome that were not mediated by HAMD scores. In contrast, sex, family 
history of depression, history of anxiety, MMSE scores, diﬃ  culties in IADLs, and UPDRS 
motor signs were related to the HARS outcome only via their relation with depression score. 
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DISCUSSION
Our results show that anxiety and depression in PD are closely related. Depression score 
appears to be the main marker for anxiety; an increase in HAMD score of 1 point resul-
ted in an increased HARS score of 1.09 (via direct as well as indirect paths). Other direct 
markers of anxiety are a previous history of depression, presence of motor fl uctuations, 
and more disease specifi c problems in ADL function. Our fi nal model (model 3, fi gure 
2) explains 65% of the variance in HARS outcome. Nonspecifi c risk factors seem to 
have a greater infl uence in the model than PD-specifi c risk factors.
Th e presence of motor fl uctuations and disease-specifi c problems in ADL functioning 
are the only signifi cant PD-related direct markers in our model. We hypothesize that this 
may refl ect situational anxiety related to 'oﬀ ' periods and to specifi c ADL activities.  Insuﬃ  -
cient coping mechanisms and psychological factors related to fl uctuations and impairments 
in ADL, such as fear of falls, future dependency, and burdening of others, in addition to 
alterations in the dopamine system, may elevate the risk for anxiety (24). Th is is in line with 
other cross-sectional studies evaluating markers for anxiety or anxiety disorders in PD (2, 3, 
8, 24, 25). Th e fi nding that PD-specifi c risk factors seem to be more contextual or situati-
onal, opens the opportunity to develop preventative measures or interventions that target 
those specifi c situations. Consistent with this, cognitive-behavioral treatments, customized 
for PD patients with anxiety and depression, are one potentially benefi cial approach (26).
With respect to other variables in our model, it is evident that levodopa aﬀ ects motor 
fl uctuations, but there was no direct eﬀ ect on the HARS score. Dopamine agonists were 
not associated with higher anxiety levels. Some studies suggest that anti-parkinsonian 
medication may be a risk factor for anxiety (9), but others do not(8, 25). Long term 
use of levodopa may lead to motor fl uctuations, in which ‘oﬀ ’ periods are associated 
with anxiety. Second, although female gender is considered an established risk factor 
for depression, it is also associated with anxiety in some studies (25, 27, 28), but not in 
others (2, 29-31). Our fi ndings suggest that women have more depressive symptoms, 
which in turn, appears to aﬀ ect severity of anxiety. Th ird, in our study disease severity 
and cognitive function also had only indirect eﬀ ects on anxiety. Some studies report a 
possible correlation between MMSE (32, 33) or disease severity (8, 30, 34) with anxiety 
disorders, while others do not (25, 27, 35, 36). Th e infl uence of cognitive decline and 
disease severity on depression scores, and subsequently on anxiety, is in line with studies 
examining risk factors for depression. Last, younger age is frequently reported to be an 
important risk factor for developing anxiety disorders (8, 35, 37), but was dropped in 
a fi rst step of optimization of the anxiety model. A possible explanation is that we con-
sidered the HARS total score but did not look at specifi c disorders. For example, social 
phobia, in particular, is associated with younger age (38).
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A recent study proposed diﬀ erent clinical profi les of anxiety in PD, with patients having 
no anxiety or depression, episodic anxiety without depression, persistent anxiety with 
depression, or both persistent and episodic anxiety with depression (22). Our model 
supports and provides a possible explanation for these profi les; apart from depression, 
only contextual or episodic factors directly infl uenced anxiety levels. Similar to depressi-
on in PD, it seems that general, non PD-specifi c risk factors are more important markers 
for anxiety in PD than PD-specifi c risk factors (10). Th is is consistent with the iden-
tifi ed phenotypes in PD, where persistent anxiety is almost invariably associated with 
depression (22). Further studies could perhaps bring more clarity in the contribution of 
specifi c subdomains of depression in the etiology of anxiety in PD. PD-specifi c markers 
for anxiety appear to be more situational, and related to 'oﬀ ' periods and disease-specifi c 
ADL disturbances. PD, in itself, appears to be a marker for anxiety, with depression and 
situational factors, in particular, exerting pre-existing vulnerability. 
Th is study has several limitations. First, the analysis was performed on an existing da-
tabase of a cross-sectional study. Parameters selected to be included in the model were 
based on availability, which implies that other important markers of anxiety, such as 
personality, coping style, marital status, or life events were not included. Inclusion of 
additional variables in the model would provide a more complete psychosomatic over-
view of all factors associated with anxiety in PD. Second, establishing true prevalence 
of anxiety or depression in PD remains a diagnostic challenge. Th e assessment is com-
plicated by symptomatic overlap between the somatic features of the neuropsychiatric 
and underlying movement disorders. Th ird, the high correlation of the HAMD and the 
HARS may introduce the problem of collinearity. However, when we compared our 
diﬀ erent models, no acceptable fi t was acquired without including the HAMD-variable. 
Only when the HAMD-variable was included, an acceptable fi t was reached, with clari-
fi cation of mediation pathways of other variables through depression – as illustrated by 
our post-hoc analysis. In addition, in a previous study focusing on modeling depression 
in PD(10), the fi nal depression model showed a good fi t without including the HARS 
variable. Th is suggests that HARS and the HAMD have diﬀ erential explanatory value 
in models of anxiety and depression. Next, it is diﬃ  cult to strictly separate markers that 
are directly related to PD and those that are not. Th is is why the authors used the terms 
“PD-specifi c” and “nonspecifi c” rather than “PD-related” and “PD-unrelated” factors. 
Finally, the study is based on a cross-sectional dataset, which implies that no causal infe-
rences can be drawn. In addition, the number of variables that could be included in the 
analysis was limited because of the sample size. However, the database was large enough 
to allow structural equation modeling analyses with a substantial number of parameters. 
Whereas our sample can be considered representative to populations that clinicians en-
counter in an outpatient clinic, our exploratory model requires confi rmation in a longi-
tudinal design, preferably with inclusion of more psychological and contextual variables. 
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Th is could clarify causal inferences and allow for investigation of whether risk factors 
change with disease progression.
In summary, in our anxiety model depression mediates the associations between most of 
the included variables and the anxiety outcome. Th e direct infl uence of motor fl uctua-
tions and PD-specifi c diﬃ  culties in ADLs suggests that, apart from depression, situatio-
nal or contextual factors seem to be the most important markers for anxiety. Clinicians 
should make every eﬀ ort to explore situational or contextual anxiety in PD patients and 
initiate individualized measures to prevent or mitigate anxiety. It is also crucial to be 
aware of the common co-occurrence of anxiety with depression but that specifi c inquiry 
is needed to identify anxiety disturbances (39) and non-PD general population factors 
mainly contribute to anxiety levels. Research to better understand the complexities of 
anxiety and depression in PD is clearly warranted. Future studies of anxiety in PD may 
further benefi t from use of a measure such as the Parkinson Anxiety Scale (PAS), which 
is better able to discriminate between episodic and non-episodic anxiety or between 
anxiety and depression (40).
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SUPPLEMENTARY FILES
Table e-1. 
Spearman coefﬁ cients between variables included in the hypothesized model. 
Dyskinesia Fluctuations UPDRS 
motor
UPDRS 
ADL
HARS 
total
HAMD 
total
IADL H&Y Depression 
Dyskinesia x .43
Fluctuations x
UPDRS motor x .64 -.44 .56
UPDRS ADL x -.52 .55
HARS total x .80 .42
HAMD total x .53
IADL x -.48
H&Y x
Depression x
Only parameters with signiﬁ cant correlation coefﬁ cients larger than 0.4 are shown. Signiﬁ cance is deﬁ ned here as 
p<0.005 (after correction for multiple testing). Variables not shown (sex, age, disease duration, MMSE score, histo-
ry of anxiety, history of depression, dysthymia, the use of a dopamine agonist or levodopa) have either no signiﬁ cant 
(p ≥ 0.005) or only weak (r ≤0.4) correlations with any of the other variables.
Abbreviations: UPDRS: Uniﬁ ed Parkinson Disease Rating Scale; ADL = Activities of Daily Living; IADL = Lawton’s 
Instrumental Activities of Daily Living scale.; HARS = Hamilton Anxiety Rating Scale; HAMD = Hamilton Depression 
Rating Scale; PD= Parkinson Disease; H&Y= Hoehn and Yahr score in ON phase
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Table e-2. 
Standardized regression coefﬁ cients of the initial (theoretical) model including 16 variables (model 1)
Parameter Dependent variable B SE β z Statistic p
Direct eﬀ ect on HARS score:
Age HARS score 0.014 0.031 0.014 0.433 0.665
Sex HARS score -0.031 0.617 -0.002 -0.050 0.960
HAMD score HARS score 1.101 0.039 0.768 28.486 0.000
FH depression HARS score -0.557 0.715 -0.031 -0.779 0.436
IADL score HARS score -0.461 0.180 -0.076 -2.556 0.011
MMSE score HARS score 0.065 0.170 0.012 0.382 0.702
History anxiety HARS score 0.190 0.634 0.011 0.300 0.764
History depression HARS score 1.657 0.669 0.098 2.476 0.013
FH anxiety HARS score 1.275 0.838 0.059 1.521 0.128
Dopamine agonist use HARS score 0.049 0.299 0.006 0.162 0.871
Levodopa use HARS score -0.126 1.374 -0.019 -0.091 0.927
Motor fl uctuations HARS score 0.410 0.499 0.065 0.821 0.412
Dyskinesias HARS score 0.289 0.642 0.053 0.450 0.652
UPDRS III (motor) HARS score 0.061 0.032 0.049 1.913 0.056
UPDRS II (ADL) HARS score 0.160 0.034 0.120 4.637 0.000
Disease duration HARS score -0.103 0.110 -0.068 -0.937 0.349
Indirect eﬀ ect on HARS score:
Levodopa use Motor fl uctuations 0.691 0.136 0.660 5.071 0.000
Disease duration Motor fl uctuations 0.003 0.025 0.013 0.121 0.903
Levodopa use Dyskinesias 0.963 0.251 0.806 3.842 0.000
Disease duration Dyskinesias -0.022 0.034 -0.081 -0.656 0.512
Disease duration Age 0.125 0.102 0.080 1.217 0.223
Disease duration IADL score -0.066 0.014 -0.266 -4.847 0.000
Disease duration MMSE score -0.024 0.017 -0.082 -1.399 0.162
Disease duration UPDRS III (motor) 0.271 0.070 0.227 3.840 0.000
Disease duration UPDRS II (ADL) 0.369 0.062 0.326 5.928 0.000
Disease duration Levodopa use 0.143 0.021 0.0626 6.698 0.000
Disease duration Dopamie agonist use 0.031 0.012 0.170 2.571 0.010
Abbreviations: FH = Family history; IADL = Lawton's Instrumental Activities of Daily Living scale; MMSE = Mini 
Mental State Examination; UPDRS = Uniﬁ ed Parkinson Disease Rating Scale; ADL = Activities of Daily Living;HAMD 
= Hamilton Depression Rating Scale; HARS = Hamilton Anxiety Rating Scale; SE = standard error. 
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Table e-3. 
Standardized regression coefﬁ cients showing direct effects within speciﬁ ed paths for the second post-hoc model. 
Parameter Dependent variable B SE β z Statistic p
Direct eﬀ ect on HARS score:
HAMD score HARS score 1.048 0.043 0.701 24.538 0.000
History depression HARS score 4.245 1.089 0.252 3.897 0.000
Motor fl uctuations HARS score 1.616 0.493 0.201 3.276 0.001
UPDRS II (ADL) HARS score 0.168 0.038 0.128 4.409 0.000
Indirect eﬀ ect on HARS score:
Levodopa use Motor fl uctuations 0.871 0.225 0.295 3.877 0.000
UPDRS ADL UPDRS III(motor) 0.763 0.048 0.692 15.842 0.000
Sex HAMD score -1.559 0.625 -0.136 -2.493 0.013
FH depression HAMD score 1.961 0.743 0.165 2.640 0.008
IADL score HAMD score -0.454 0.141 -0.114 -3.212 0.001
MMSE score HAMD score -0.549 0.164 -0.166 -3.351 0.001
History anxiety HAMD score 2.327 0.678 0.199 3.432 0.001
UPDRS III (motor) HAMD score 0.211 0.034 0.266 6.190 0.000
MMSE score IADL score 0.167 0.038 0.202 4.438 0.000
MMSE score UPDRS II(ADL) -0.640 0.214 -0.170 -2.995 0.003
IADL score UPDRS II (ADL) -4.699 0.530 -0.538 -8.870 0.000
Abbreviations: FH = Family history; IADL = Lawton's Instrumental Activities of Daily Living scale; MMSE = Mini 
Mental State Examination; UPDRS = Uniﬁ ed Parkinson Disease Rating Scale; ADL = Activities of Daily Living; HAMD 
= Hamilton Depression Rating Scale;HARS = Hamilton Anxiety Rating Scale; SE = standard error.
Broen MPG, Moonen AJH, Kuijf ML, Dujardin K, Marsh L, Richard IH, 
Starkstein SE, Martinez-Martin P, Leentjens AFG
Parkinsonism Relat Disord. 2015 Feb;21(2):142-6.
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ABSTRACT
Introduction: 
Several studies have validated the Hamilton Depression Rating Scale (HAMD) in pa-
tients with Parkinson’s disease (PD), and reported adequate reliability and construct 
validity. However, the factorial validity of the HAMD has not yet been investigated. Th e 
aim of our analysis was to explore the factor structure of the HAMD in a large sample 
of PD patients. 
Methods: 
A principal component analysis of the 17-item HAMD was performed on data of 341 
PD patients, available from a previous cross sectional study on anxiety. An eigenvalue 
≥1 was used to determine the number of factors. Factor loadings ≥ 0.4 in combination 
with oblique rotations were used to identify which variables made up the factors. Kai-
ser-Meyer-Olkin measure (KMO), Cronbach’s alpha, Bartlett’s test, communality, per-
centage of non-redundant residuals and the component correlation matrix were compu-
ted to assess factor validity.
Results: 
KMO verifi ed the sample's adequacy for factor analysis and Cronbach’s alpha indicated 
a good internal consistency of the total scale. Six factors had eigenvalues ≥1 and together 
explained 59.19% of the variance. Th e number of items per factor varied from 1 to 6. 
Inter-item correlations within each component were low. Th ere was a high percentage 
of non-redundant residuals and low communality.
Conclusion: 
Th is analysis demonstrates that the factorial validity of the HAMD in PD is unsatis-
factory. Th is implies that the scale is not appropriate for studying specifi c symptom 
domains of depression based on factorial structure in a PD population. 
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INTRODUCTION
Depression is common in patients with Parkinson’s disease (PD) and recent studies 
show that up to 35% of patients have clinically relevant depressive symptoms (1). Ade-
quate recognition and treatment lead to a better quality of life (2), which underlines the 
importance of valid depression scales. Th e Hamilton Depression Rating Scale (HAMD) 
is the most commonly used measure of depressive symptoms (3). It was developed in 
the late 1950s to assess the eﬀ ectiveness of the fi rst generation of antidepressants (4). 
Th roughout the years, several studies have demonstrated adequate reliability and con-
struct validity of the HAMD in PD patients (5, 6). However, none of these studies 
addressed the factor structure of the HAMD in this population. Factor analyses of the 
HAMD in the general population are not easily generalizable to the PD population, 
since symptoms of PD and depression may overlap. Th e aim of this analysis is to explore 
the multidimensionality of the HAMD in a large PD population by conducting an 
exploratory factor analysis. 
METHOD
Population and assessment
Th e present study is a secondary analysis of a cross sectional observational study con-
ducted in 2008 and 2009 that was aimed at validating anxiety rating scales. (7). Th e 
database included 341 patients with PD, diagnosed according to the Queen Square 
Brain Bank clinical criteria. Inclusion and exclusion criteria and assessment procedures 
were published previously (7). All patients underwent a comprehensive neurologic and 
neuropsychiatric assessment, including the 17-item HAMD. Th e HAMD, an inter-
view-based rating scale, consists of 17 items: 16 question-based items and one obser-
vational item. Th e scale covers the whole spectrum of depressive symptoms, including 
aﬀ ective, cognitive and somatic symptoms. Th e item scores range from 0-4 (symptom is 
absent, mild, moderate, or severe) or 0-2 (absent, slight or trivial, clearly present). Th e 
total score can range from 0 to 54. A cut-oﬀ  score of 9/10 has been suggested for scree-
ning purposes in PD patients (6). Th e presence of a DSM-IV-defi ned depressive disor-
der was determined using the Mini International Neuropsychiatric Inventory (MINI), 
sections for depression (A, B). Th e local Medical Ethics Committees of all participating 
institutions approved the study. Patients gave written informed consent before inclusion 
in the study.
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Statistical analyses
A principal component analysis (PCA) was conducted on the 17 items of the HAMD. 
Initially, we used an eigenvalue ≥1 to determine the number of factors, in combination 
with scree plots. Since we expected that underlying factors may be related, we used obli-
que rotation (direct oblimin) to optimise confi guration on factors, allowing for maxi-
mum amount of non-orthogonality (Delta=0). We used factor loadings with an absolute 
value greater than 0.4, which explains around 16% of the variance in the variable (8). 
When items loadings were >0.4 on more than one factor, one factor was selected based 
on the clinically most plausible solution. We then compared pattern and structure ma-
trices to reveal the infl uence of shared variance. Communality was calculated to show 
the proportion of variance explained by the extracted factors. In addition, we conducted 
a Bartlett’s test to check for intercorrelation between variables, measured the percentage 
of non-redundant residuals and calculated the component correlation matrix to check 
for correlations between the factors. Th e Kaiser-Meyer-Olkin measure of sampling ade-
quacy (KMO) was computed to determine adequacy of sample size and the internal 
consistency of the scale was measured with Cronbach’s alpha (α). To determine the most 
appropriate number of factors, we re-run the analysis with a fi xed number of 2, 3, 4, 5, 
and 7 extracted factors. All analyses were computed with SPSS 20 (Chicago).
RESULTS
Th e study population consisted of 207 men and 134 women (total n=341) with an aver-
age age of 64.8 years (SD 9.2; range 34 to 87), mean disease duration of 8.3 years (SD 
5.6), mean UPDRS III score 26.4 (SD 12.4), and an average Hoehn and Yahr stage of 
2. Half of the patients experienced on/oﬀ  fl uctuations and 39% suﬀ ered from dyskine-
sias. Eighty-fi ve percent of patients used levodopa and 62% dopamine agonists. Mean 
MMSE score was 28.5 (SD 1.7). Based on the MINI, 48 participants (14%) met the 
DSM IV criteria for a current major depressive episode, 19 (6%) met the DSM IV cri-
teria for dysthymia, and 64 (19%) suﬀ ered from clinically relevant depressive symptoms 
(defi ned here as a HAMD score ≥12), but did not meet the DSM IV diagnostic criteria 
for major depressive episode or dysthymia. Th e mean HAMD-score of patients with a 
major depressive episode was 16.8 (SD 5.5) and 6.2 (SD 4.4) for patients without a ma-
jor depressive episode. Cronbach’s alpha (α) was 0.79, which indicates a good reliability 
of the total HAMD scale. More demographic and disease-related characteristics of the 
sample are listed in Table s1 of the supplementary data.
Th e Kaiser-Meyer-Olkin measure verifi ed the sampling adequacy for the analysis. A 
KMO value of 0.78 confi rms that sampling adequacy was tolerable. All but one KMO 
values for individual items were above the acceptable limit of 0.5. Item 17 Insight- no 
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acknowledgment of illness had an individual KMO of 0.45. Bartlett’s test of sphericity 
indicated that correlations between items were suﬃ  ciently large for PCA (�2 (136) = 
1114.315, p <0.01). An initial analysis was conducted to obtain eigenvalues for each 
component in the data. Six components had eigenvalues over Kaiser’s criterion of 1 and 
together they explained 59.2% of the variance. Th e scree plot showed many small in-
fl exions. Table 1 shows the factor loadings after rotation for the six factor solution based 
on the Kaiser criterion. Only item 7 Di  culty with work and activities had more than 
one factor loading >0.4. Based on the clinically most plausible solution, it was decided 
to place this item in component 1.  
Table 1.
Rotated factor loadings (N=341)
Rotated Factor Loadings
Item 1 2 3 4 5 6
1. Depressed mood 0.46 -0.02 -0.35 -0.14 0.22 0.06
2. Feelings of guilt 0.08 0.04 -0.71 0.05 0.05 -0.04
3. Suicide 0.11 0.09 -0.74 -0.03 -0.04 -0.04
4. Insomnia early- falling asleep -0.07 -0.46 -0.14 -0.09 0.31 -0.23
5. Insomnia middle- waking during night 0.16 -0.80 0.18 -0.04 0.02 0.01
6. Insomnia late- early morning waking 0.06 -0.72 -0.07 0.11 -0.03 0.20
7. Diﬃ  culty with work and activities 0.42 0.06 -0.06 -0.16 0.44 0.26
8. Retardation- psychomotor 0.59 0.23 0.10 0.05 0.30 0.11
9. Agitation -0.06 -0.09 -0.66 -0.00 -0.04 0.16
10. Anxiety- psychic 0.78 -0.11 -0.09 0.17 -0.15 -0.11
11. Anxiety- somatic 0.62 -0.19 -0.24 -0.07 -0.07 0.10
12. Somatic- gastro-intestinal and appetite -0.16 -0.01 -0.14 0.39 0.21 0.59
13. Somatic- general -0.08 0.01 -0.29 0.11 0.71 -0.08
14. Genital symptoms 0.09 -0.11 0.22 -0.03 0.68 0.05
15. Hypochondriasis 0.61 -0.15 -0.01 0.02 0.01 -0.03
16. Loss of weight 0.06 -0.10 -0.02 -0.16 -0.08 0.80
17. Insight- no acknowledgment of illness 0.15 -0.03 0.02 0.92 -0.00 -0.08
Eigenvalues 4.06 1.52 1.22 1.13 1.09 1.04
% of variance 23.89 8.96 7.15 6.67 6.41 6.11
α 0.77 0.53 0.60 - 0.38 0.35
Note: Factor loadings over .40 appear in bold. Results of pattern analysis are shown. 
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Table 2 gives an overview of the items clustering when 2, 3, 4, 5, 6 or 7 components 
were extracted. Results following PCA indicated that component 1 represents the core 
symptoms of depression: depressed mood, anxiety, decreased activity, psychomotor 
retardation and hypochondriasis. Component 2 represents sleep diﬃ  culties and com-
ponent 3 clusters delusions, agitation and suicide together. Component 4 represents 
the only observation item insight of illness. Component 5 includes the general soma-
tic symptoms and loss of libido, component 6 gastrointestinal symptoms and loss of 
weight. However, since a factor must consist of at least two joined items and component 
4 represents only one item, the total number of genuine factors is 5. 
Correlations
Although Bartlett’s test turned out to be signifi cant, the correlation matrix (Supplemen-
tary data, Table s2) shows that correlations between several items are not very strong (all 
r<0.3).  Especially item 17 Insight (acknowledgment of illness) appears to be weakly cor-
related to other items (all r<0.2). In addition, variables 4 Insomnia early (falling asleep), 
12 Somatic (gastro-intestinal and appetite), 14 Genital symptoms and 16 Loss of weight all 
have correlations below 0.3. To assess the fi t of the model we looked at the diﬀ erences 
between the observed correlations and the correlations based on the model, using the 
reproduced matrix (Supplementary data, Table s3). A good model should have low re-
sidual values (<0.05). However, this model shows 52% non-redundant residuals with 
absolute values greater than 0.05.
Communality
Communality measures the proportion of common variance present in a variable. Ac-
cording to Kaiser’s criterion, an individual value of >0.7 or an average value of >0.6 
when sample size exceeds 250, indicates suﬃ  cient communality. In this sample, only 
2 items (5 Insomnia middle- waking during night) and 17 Insight have values >0.7. Th e 
average of the communalities (10.062/17) = 0.59 which is just below the acceptable 0.6. 
None of the variables have values below 0.4.  
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Table 2. 
Overview of factor components when 2-7 factors are calculated.
Number of 
factors
2 3 4 5 6 7
Communality 0.33 0.40 0.47 0.53 0.59 0.65
% variance 
explained
33 40 47 53 59 65
1. Depressed 
mood
4. Insomnia 
early- falling 
asleep
2. Feelings of 
guilt
1. Depressed 
mood
1. Depressed 
mood
1. Depressed 
mood
5. Insomnia 
middle- waking 
during night
5. Insomnia 
middle- waking 
during night
3. Suicide 7. Diﬃ  culty 
with work and 
activities
7. Diﬃ  culty 
with work and 
activities
8. Retardation- 
psychomotor
6. Insomnia 
late- early 
morning waking
6. Insomnia 
late-early 
morning waking
9. Agitation 8. Retardation- 
psychomotor
8. Retardation-  
psychomotor
10. Anxiety- 
psychic 
7. Diﬃ  culty 
with work and 
activities
10. Anxiety- 
psychic
5. Insomnia 
middle- waking 
during night
10. Anxiety- 
psychic 
10. Anxiety- 
psychic
11. Anxiety- 
somatic
8. Retardation- 
psychomotor
11. Anxiety-
somatic
6. Insomnia 
late- early 
morning waking
11. Anxiety- so-
matic
11. Anxiety- so-
matic
15. Hypochon-
driasis
10. Anxiety- 
psychic 
15. Hypochon-
driasis
10. Anxiety- 
psychic 
15. Hypochon-
driasis
15. Hypochon-
driasis
5. Insomnia 
middle- waking 
during night
11. Anxiety- 
somatic
2. Feelings of 
guilt
11. Anxiety- 
somatic
16. Loss of 
weight
4. Insomnia 
early-  falling 
asleep
6. Insomnia 
late- ealy 
morning waking
14. Genital 
symptoms
3. Suicide 15. Hypochon-
driasis
2. Feelings of 
guilt
5. Insomnia 
middle- waking 
during night
2. Feelings of 
guilt
15. Hypochon-
driasis
9. Agitation 1. Depressed 
mood
3. Suicide 6. Insomnia 
late- early 
morning waking
3. Suicide
2. Feelings of 
guilt
1. Depressed 
mood
7. Diﬃ  culty 
with work and 
activities
9. Agitation 2. Feelings of 
guilt
9. Agitation
3. Suicide 7. Diﬃ  culty 
with work and 
activities
8. Retardation- 
psychomotor
13. Somatic- 
general
3. Suicide 12. Somatic- 
gastro-intestinal 
and appetite
9. Agitation 8. Retardation- 
psychomotor
13. Somatic- 
general
14. Genital 
symptoms 
9. Agitation 16. Loss of 
weight
12. Somat-
ic- gastro-in-
testinal and 
appetite
12. Somat-
ic- gastro-in-
testinal and 
appetite
14. Genital 
symptoms 
12. Somat-
ic- gastro-in-
testinal and 
appetite
17. Insight- no 
acknowledg-
ment of illness
7. Diﬃ  culty 
with work and 
activities
13. Somatic- 
general
13. Somatic- 
general
12. Somatic-
gastro-intestinal 
and appetite
17. Insight- no 
acknowledg-
ment of illness
13. Somatic- 
general
13. Somatic- 
general
14. Genital 
symptoms
16. Loss of 
weight
4. Insomnia 
early- falling 
asleep
14. Genital 
symptoms 
14. Genital 
symptoms 
17. Insight- no 
acknowledg-
ment of illness
5. Insomnia 
middle- waking 
during night
12. Somatic- 
gastro-intestinal 
and appetite
17. Insight- no 
acknowledg-
ment of illness
6. Insomnia 
late- early 
morning 
waking
16. Loss of 
weight
4. Insomnia 
early- falling 
asleep
Note: Factor loadings from the pattern matrix are used.
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Pattern and structure matrix
Th e structure matrix diﬀ ers from the pattern matrix in that shared variance is not ig-
nored. Th e pattern matrix contains information about the unique contribution of a 
variable to a factor. When we compared the pattern with the structure matrix, the only 
diﬀ erence was that item 7 (Di  culty with work and activities) had a higher factor loading 
on component 1 (0.57), instead of component 5 (0.56) (Supplementary data, Table 
s4). Th e component correlation matrix (Supplementary data, Table s5) shows that there 
were little or no relationships between the factors (all r <0.3), which were suspected 
since we allowed maximum amount of non-orthogonality.
Cronbach’s alpha
To measure the scale reliability we calculated the Cronbach’s alpha (α) for each compo-
nent. Component 1 (item 1, 7, 8, 10, 11, 15) had an α of 0.77. Components 2, 3, 5 
and 6 had α values of 0.53, 0.60, 0.38 and 0.35 respectively. Component 4 consisted of 
1 item and had no α. In general, a value of 0.7 to 0.8 is considered an acceptable value, 
indicating suﬃ  cient reliability. However, in psychological constructs values below 0.7 
can be expected because of the diversity of the constructs being measured. In addition, 
the value of α is infl uenced by the number of items. As the number of items increase α 
will also increase. Subsequently, component 1 which consists of 6 items had a higher α 
in comparison with component 5 and 6 (2 items). 
Components
After extracting 2, 3 and 4 components the factor loading of respectively 3, 2 and 1 
variables were below 0.4, which is in general the absolute value indicating an important, 
signifi cant factor loading. With 5 or 6 extracted components, the clustering variables 
were fairly similar, with the only diﬀ erent items being 16 Loss of weight and 17 Insight 
(Table 2). With 7 extracted components item 4 Insomnia early was split oﬀ  and item 7 
Di  culty with work and activities made up a component with items 12 Somatic- general 
and 14 Genital symptoms. As expected, communalities and total percentage of explained 
variance increased as the number of components increased likewise. 
DISCUSSION
Th is PCA of the HAMD in a large sample of PD patients revealed six components. 
However, because of low correlations between variables within the components, as well 
as the varying number of items per component (varying from 1 to 6), and a high per-
centage of non-redundant residuals and low communality, factor validity appeared to 
be unsatisfactory. 
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We believe that our sample, with respect to demographic and disease characteristics as 
well as medication use, is comparable to a population that clinicians encounter in out-
patient clinics (9,10). Th e HAMD was initially developed to measure change over time 
in depressive symptoms in a psychiatric population with known depressive disorders. 
Th roughout the years the scale utility has been studied in general populations as well as 
in neurological conditions and shown to have a good predictive validity for presence of 
major depression. It is remarkable how well the HAMD has performed in psychometric 
evaluations, especially since Hamilton mentioned there was “room for improvement” 
and the HAMD remained almost unchanged after 50 years in practice (4). Th ere are 
only a few studies that describe a factor analysis of the HAMD in the general populati-
on (11). Th ese studies argue that the HAMD is admittedly multidimensional, but with 
poor replication across samples. In agreement, insomnia items appeared to load consis-
tently on the same factor in our study. However, other components such as depressed 
mood, suicide and psychic anxiety or a component of psychic anxiety, somatic anxiety 
and agitation were not found. A possible explanation for the fact that item 17 made up 
a component of its own in our analysis is that item 17 is the only observational item 
of the scale and requires clinical interpretation and experience. Some patients predo-
minantly form anhedonia and may not appear depressed, which makes rating diﬃ  cult. 
Th e reported number of factors identifi ed in studies in the general population ranged 
from two to eight (11). In addition, a meta-analysis of factor structures of four depres-
sion questionnaires, including the HAMD, showed that a four-component solution 
appeared to be the most generalizable, although it was mostly based on small studies 
(12). Comparable to the factorial structure of the HAMD across studies in the general 
population, it appears also unsatisfactory in the PD population. However, other clini-
metric properties of the scale are satisfactory. Several other studies have shown that the 
scale has a high sensitivity and specifi city, good inter-rater reliability and high negative 
predictive value with acceptable positive predictive values (6). Th e scale is appropriate 
as a screening measure for depression, evaluating its severity and monitor change over 
time. However, our analysis proves that it is not suitable for studying specifi c symptom 
domains based on factorial structure in a PD population. Th is aids in interpreting study 
results and designing future studies in PD. In addition, the analysis complements the 
validation of the most widely used depression scale in PD. 
In conclusion, our study shows that the HAMD is a multidimensional scale. Although 
studies have shown adequate reliability and construct validity of the HAMD in PD pa-
tients, factor validity is unsatisfactory. As such, there is still room for improvement, just 
as Hamilton stated more than 50 years ago. 
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SUPPLEMENTARY FILES
Table s1. 
Demographic and disease characteristics of the sample (n = 341).
Variable Percentage Mean (SD)
Female sex 39
Age 64.8 (9.2)
Duration of PD 8.3 (5.6)
UPDRS section 2 (ADL) 11.6 (6.8)
UPDRS section 3 (motor) 26.4 (12.4)
UPDRS section 4 (complications) 3.5 (3.5)
Hoehn & Yahr stage (median; range) 2 (1-5)
On/oﬀ  fl uctuations 52
Dyskinesias 30
Major depression 14
Dysthymia 6
Previous history depression 46
Previous history anxiety disorder 32
Family history depression 33
Family history anxiety disorder 19
Family history of PD 20
HAMD score 7.7 (5.9)
HARS score 11.3 (8.5)
IADL score 7 (1.5)
MMSE score 28.5 (1.7)
Use of levodopa 85
Use of dopamine-agonist 62
Use of antidepressant 34
PD = Parkinson's Disease; UPDRS = Uniﬁ ed Parkinson's Disease Rating Scale; ADL = Activities of Daily Living; 
HAMD = Hamilton Depression Scale; HARS = Hamilton Anxiety Rating Scale; IADL = Lawton's Instrumental Activi-
ties of Daily Living scale; MMSE = Mini Mental State Examination.
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Table s4. 
Rotated factor loadings, structure matrix
Item 1 2 3 4 5 6
1. Depressed mood 0.61 -0.19 -0.49 -0.11 0.40 0.18
2. Feelings of guilt 0.24 -0.08 -0.73 0.11 0.18 0.07
3. Suicide 0.24 -0.03 -0.73 0.03 0.09 0.06
4. Insomnia early- falling asleep 0.08 -0.50 -0.20 -0.12 0.34 -0.26
5. Insomnia middle- waking during night 0.28 -0.81 0.04 -0.09 0.12 0.01
6. Insomnia late- early morning waking 0.24 -0.73 -0.21 0.10 0.10 0.22
7. Diﬃ  culty with work and activities 0.57 -0.09 -0.24 -0.14 0.56 0.37
8. Retardation- psychomotor 0.61 0.09 -0.08 0.05 0.41 0.23
9. Agitation 0.13 -0.17 -0.67 0.06 0.09 0.22
10. Anxiety- psychic 0.77 -0.25 -0.36 0.15 0.06 0.03
11. Anxiety- somatic 0.72 -0.35 -0.40 -0.07 0.15 0.22
12. Somatic- gastro-intestinal and appetite 0.01 -0.01 -0.24 0.45 0.26 0.63
13. Somatic- general 0.14 -0.10 -0.39 0.13 0.73 0.01
14. Genital symptoms 0.23 -0.18 0.07 -0.04 0.68 0.10
15. Hypochondriasis 0.64 -0.27 -0.17 0.00 0.17 0.08
16. Loss of weight 0.20 -0.11 -0.12 -0.11 0.03 0.80
17. Insight- no acknowledgment of illness 0.12 -0.02 -0.08 0.91 0.03 0.01
Note. Factor loadings over .40 appear in bold. 
Broen MPG. Leentjens AFG, Köhler S, Kuijf ML, McDonald WM, Richard IH. 
Parkinsonism Relat Disord. 2016 Feb;23:80-5. 
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Trajectories of recovery in depressed Parkinson’s disease 
patients treated with paroxetine or venlafaxine
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ABSTRACT
Introduction: 
Depression is considered a syndrome with a constellation of symptoms that are fre-
quently categorized into 3 domains including aﬀ ective, somatic and cognitive. Th ere 
has been limited research into the domain specifi c magnitude or relative timing of tre-
atment response in patients with Parkinson’s disease (PD). In addition, antidepressant 
trials involving patients with PD have demonstrated a similar robust placebo response 
to that seen in other populations.  However, the timing of the placebo response has not 
been carefully studied. 
Methods: 
We studied diﬀ erential responses to antidepressant treatment in aﬀ ective, somatic and 
cognitive domains of depression. Patients were treated for twelve weeks with placebo, 
venlafaxine or paroxetine as part of the Study of Antidepressants in Parkinson’s Disease 
(SAD-PD) randomized controlled trial. Depressive symptoms were evaluated with three 
commonly used rating scales.
Results: 
All symptom domains improved during the study period, Th ere was a signifi cant place-
bo eﬀ ect, especially in the fi rst two weeks that had diminished by week 12. Compared 
to placebo, the aﬀ ective symptoms signifi cantly improved during treatment as early as 
week 4, followed by the somatic symptoms of depression in week 6 and cognitive symp-
toms in week 8. Th e largest response was seen in the aﬀ ective domain. 
Conclusion: 
In depressed PD patients treated with venlafaxine or paroxetine, aﬀ ective symptoms 
improved fi rst, followed by somatic symptoms and cognitive symptoms. Th ese fi ndings 
could guide patient counselling and increase patient compliance by informing about the 
expected treatment responses. Th e substantial placebo eﬀ ect underlines the importance 
of a suﬃ  ciently long study period in future studies.
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INTRODUCTION
Clinically signifi cant depressive symptoms are found in up to 50% of Parkinson’s di-
sease (PD) patients, with an estimated prevalence of major depressive disorder of 17% 
(1). Depressed PD patients report a decreased quality of life and consistently rate the 
eﬀ ect of their psychiatric disturbances as more detrimental to their well-being than the 
severity of motor symptoms (2,3). However, only about 20% of depressed PD patients 
receives treatment for depression (4) and despite extensive research, there is still dis-
cussion about the optimal treatment strategy (5,6). In addition, several studies showed 
that up to 67% of PD patients have a low medication adherence (7-9). Mood disorders, 
especially depressive disorders, seem to be the most important factor for non-adherence 
(10). Studies in psychiatric populations show that education of depressed patients when 
starting antidepressants greatly improves compliance (11). 
Symptoms of depression are frequently subdivided in three domains including aﬀ ective, 
somatic and cognitive symptoms (concentration and ideational). Research exploring 
domain specifi c magnitude or timing of treatment response is scarce. A more thorough 
understanding of this response in depressed PD patients could aid patient counseling by 
informing the patients about the expected response. In addition, although antidepres-
sant trials involving PD patients have demonstrated robust placebo responses similar to 
that seen in other population, there is no thorough study of the timing of this response.
Th e aim of this analysis is to explore diﬀ erential response patterns to treatment with ven-
lafaxine or paroxetine in the aﬀ ective, somatic and cognitive domains of depressed PD 
patients using data of the largest placebo-controlled randomized controlled trial (RCT) 
of antidepressants for the treatment of depression in PD patients to date. 
METHODS
Th is study is a secondary analysis on the dataset of the Study of Antidepressants in PD 
(SAD-PD) (12). Th is study showed superior eﬃ  cacy of treatment with venlafaxine or 
paroxetine over placebo treatment in depressed PD patients.  
Participants
Th e SAD-PD study enrolled 115 participants from 20 centers in the United States, 
Canada, and Puerto Rico from 2005 through 2009. Patients with idiopathic PD, diag-
nosed according to the Queen Square Brain Bank criteria (13) had to meet diagnostic 
criteria of the 4th edition of the Diagnostic and Statistical Manual (DSM-IV) (14) for 
major depressive disorder, dysthymic disorder or minor depression. Patients with de-
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mentia as defi ned by the DSM-IV criteria, or those with a Mini Mental Sate Examina-
tion (MMSE) (15) score <23 were excluded. Antidepressant medication other than the 
study drugs, as well as antipsychotics and MAO inhibitors were not permitted. 
Standard protocol approvals, registrations, and patient consents
Th e study was approved by the local Medical Ethics Committees of all participating 
institutions. Patients gave written informed consent before inclusion in the study. Th e 
study was registered with clinicaltrials.gov (registration no. NCT00086190).
Assessment and randomization
During a screening visit informed consent was obtained and eligibility criteria were 
verifi ed. During the baseline visit (t=0) the participants were randomized to venlafaxi-
ne, paroxetine or placebo in a 1:1:1 ratio. Double-blind treatment lasted 12 weeks and 
consisted of a 6-week dosage titration and a 6-week maintenance period. Th e fi rst two 
weeks participants received 10mg of paroxetine or 37,5mg of venlafaxine XR or mat-
ching placebos. Th e following 4 weeks the investigator then adjusted the dosage as ne-
cessary and tolerated up to a maximum daily dosage of 40mg for paroxetine and 225mg 
for venlafaxine XR to achieve the optimal dosage. Patients were evaluated at 2, 4, 6, 8 
and 12 weeks after randomization. During these evaluations participants were assessed 
in the “on” state. Antidepressant eﬃ  cacy was rated by the 17-item Hamilton Depression 
Rating Scale (HAMD) (16), Montgomery-Åsberg Depression Rating Scale (MADRS) 
(17) and the Beck Depression Inventory II (BDI-II) (18).
Statistical methods
None of the depression rating scales used in the study has a satisfactory factorial structu-
re on the basis of which symptom domains could be defi ned (19). In order to formulate 
symptom domains we subdivided the items of the HAMD, BDI-II and MADRS into 
“aﬀ ective”, “somatic” or “cognitive”, based on face validity (Table 1). Only items with 
clear aﬀ ective, cognitive or somatic characteristics were included. Items that could not 
be easily attributed to one of these domains, such as agitation, were not included. Th e 
cognitive domain consisted of both symptoms of cognitive dysfunction (such as con-
centration diﬃ  culties, lack of insight) as well as of depressive-related ideation. Th e fi nal 
aﬀ ective domain included 14 items, the cognitive domain 14 items and the somatic do-
main 16 items. All three domains showed excellent internal consistency with Cronbach’s 
α 0.96, 0.95 and 0.94 respectively. Since the three depression scales had diﬀ erent ranges, 
means and standard deviations, we standardized the scores by calculating z-scores of 
each domain. First we calculated the z-score of the patient per scale and per domain, 
after which we averaged the domain-specifi c z-scores on the three scales into one single 
score.  
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Table 1. 
Overview of HAM-D, MADRS and BDI-II items classiﬁ ed per domain based on face validity. 
Aﬀ ective domain
(N=14)
Cognitive domain
(N=14)
Somatic domain
(N=16)
HAM-D 1. Depressed mood HAM-D 2. Feelings of guilt HAM-D 4. Insomnia early
HAM-D 3. Suicide HAM-D 15. Hypochondriasis HAM-D 5. Insomnia middle
HAM-D 7. Loss of interest in work 
and activities
HAM-D 17. Insight illness HAM-D 6. Insomnia late
HAM-D 10. Anxiety (psychological) MADRS 6. Concentration diﬃ  cul-
ties
HAM-D 11. Anxiety somatic
MADRS 1. Apparent sadness MADRS 9. Pessimistic thoughts HAM-D 12. Somatic symptoms (GI)
MADRS 2. Reported Sadness BDI 2. Pessimism HAM-D 13. Somatic symptoms 
(general)
MADRS 8. Inability to feel BDI 3. Past failure HAM-D 14. Genital symptoms 
MADRS 10. Suicidal thoughts BDI 5. Guilty feelings HAM-D 16.  Loss of weight
BDI 1. Sadness BDI 6.  Punishment feelings MADRS 4. Reduced sleep
BDI 4. Loss of pleasure BDI 7. Self-dislike MADRS 5. Reduced appetite
BDI 9.  Suicidal thoughts BDI 8. Self-criticalness MADRS 7. Lassitude
BDI 10. Crying BDI 13. Indecisiveness BDI 15. Loss of energy
BDI 12. Loss of interest BDI 14. Worthlessness BDI 16. Changes in sleep pattern
BDI 17. Irritability BDI 19. Concentration diﬃ  culty BDI 18. Changes in appetite
BDI 20.  Tiredness or fatigue
BDI 21. Loss of interest in sex
Abbreviations: HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; 
BDI, Beck Depression Inventory II.
Since there was no diﬀ erence in the depression outcome between patients treated with 
venlafaxine and paroxetine (12), we decided to combine these two treatment groups 
to increase the power of our analysis. Th e between group diﬀ erence in change in do-
main-specifi c z-scores compared to baseline was evaluated at 2,4,8 and 12 weeks using 
a repeated measures analysis of variance (rm-ANOVA). Th e dependent variable was the 
domain-specifi c averaged z-score, and the within-subject factor was “time” (6-levels: 
baseline, week 2,4,6,8 and 12). Since Mauchly’s test of sphericity was signifi cant, all 
F- and df-values were adjusted following the method of Greenhouse-Geisser if Epsi-
lon was <0.75 (cognitive domain) or Huynh-Feldt if Epsilon was >0.75 (aﬀ ective and 
somatic domain). Th e between-subject factor was group (“placebo” or “active treatment”). 
Th e interaction between treatment and time was of most interest as it indicates diﬀ erential 
improvement between groups in the dependent variable. All analyses were computed with 
SPSS 21 (Chicago). In order to further test whether change across domains was signifi cantly 
diﬀ erent, we compared the delta scores per domain (defi ned as the score at last observation 
minus the score at baseline) using three paired-sample t-tests in a post-hoc analysis.
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RESULTS
A total of 115 subjects were randomized to receive paroxetine (n=42), venlafaxine XR 
(n=34), or placebo (n=39). Eighteen subjects (16%) withdrew participation and 4 (3%) 
were not assessed on all measurement points (2,4,6,8,12 weeks). For the fi nal analyses 
the placebo group consisted of 32 subjects and the treatment group of 61 (33 on pa-
roxetine and 28 on venlafaxine). Th e demographic and disease characteristics of the two 
groups are listed in Supplementary table 1. Fifty-nine percent of patients in the active 
treatment group had a diagnosis of major depressive disorder versus 56% in the placebo 
treated group. Th e active treatment group was slightly older than the placebo treated 
group (64.2 years versus 61.4 years), mean disease duration in the treatment group was 
5.3 years, in the placebo group 5.5 years. Mean scores on the HAM-D, MADRS and 
BDI-II at baseline were comparable in both groups. 
RM-ANOVA showed a signifi cant time eﬀ ect in all three domains for both groups, with 
a signifi cant group-by-time interaction in the 3 depression symptom domains (aﬀ ective: 
Wilks’ Lambda = 0.86, F (4.24, 73.78) = 4.17, p = 0.003; somatic: Wilks’ Lambda 
= 0.86, F (3.73, 65.08) = 3.36, p = 0.012; cognitive: Wilks’ Lambda = 0.87, F (3.4, 
59.16) = 4.42, p = 0.003). We then examined the treatment-by-time interaction for 
each measurement moment (Supplementary table 2). Th ere was a signifi cant (p<0.05) 
treatment-by-time interaction in the aﬀ ective domain from week 4 onwards (Figure 1), 
suggesting greater reduction in the treatment group. In addition, rm-ANOVA resulted 
in a signifi cant treatment-by-time interaction on the somatic domain from week 6 on-
wards (Figure 2) and in the cognitive domain from week 8 onwards (Figure 3). In all 
three domains the placebo eﬀ ect diminished over time, with even an increase of mean 
z-scores in week 12. Aﬀ ective symptoms seemed to improve the most (z-score at week 
12 = -1.6), followed by cognitive (z-score= -1.3) and somatic symptoms (z-score= -1.0). 
Post hoc t-tests showed that, at the last follow-up, the treatment group had improved 
signifi cantly more in the aﬀ ective than in the somatic (mean diﬀ erence = -0.65, t = 
-6.13, df = 60,  p<.001) and in the cognitive domain (mean diﬀ erence = -0.30, t = -2.74, 
df = 60,  p=.008). In addition, the cognitive domain had improved signifi cantly more 
than the somatic domain (mean diﬀ erence = -0.35, t = -2.80, df = 60,  p=.007).
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Figure 1. 
Trajectories of symptom change in the affective domain.
Note: An asterisk is shown when there was a signiﬁ cant difference (<.05) between the scores of the placebo and the 
treatment group; Standard error bars are displayed.  
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Figure 2. 
Trajectories of symptom change in the somatic domain.
Note: An asterisk is shown when there was a signiﬁ cant difference (<.05) between the scores of the placebo and the 
treatment group; Standard error bars are displayed.  
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Figure 3. 
Trajectories of symptom change in the cognitive domain.
Note: An asterisk is shown when there was a signiﬁ cant difference (<.05) between the scores of the placebo and the 
treatment group; Standard error bars are displayed.  
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DISCUSSION
Th is study shows that all 3 domains of depressive symptoms (aﬀ ective, somatic and 
cognitive) improve during treatment with venlafaxine or paroxetine compared to the 
placebo treated group. Aﬀ ective symptoms showed a signifi cant response to treatment 
from week 4 onwards, followed by somatic symptoms from week 6 onwards and cogni-
tive symptoms from week 8 onwards. At the end of the trial, after 12 weeks, the aﬀ ective 
symptoms showed the largest response to treatment, followed by cognitive (ideational) 
and somatic symptoms.  As such, our study does not support the older vision that im-
provement of aﬀ ect is preceded by improvement in energy or volition that often was 
used to explain suicidal behavior in patients shortly after the initiation of antidepressant 
therapy. 
A signifi cant placebo eﬀ ect is seen in all three domains, most prominently in the fi rst 2 
weeks, with a trend of a reducing placebo eﬀ ect towards week 12. 
In clinical research, RCTs of treatment of depression are generally designed to evaluate 
eﬃ  cacy at endpoint, and not to examine the onset and time course of improvement. 
A recent meta-analysis (6) of the eﬃ  cacy of antidepressant therapies in depressed PD 
patients included 9 RCTs, of which four studies used change in the MADRS score as 
the primary outcome, another four used the HAMD and one study used the clinician 
rated Inventory of Depressive Symptomatology (IDS-C). However, changes in total 
scores of depression scales may not refl ect improvements in specifi c symptom domains, 
e.g. there may be a positive eﬀ ect on aﬀ ective symptoms, but a negative eﬀ ect on sleep 
as an early side eﬀ ect of the treatment drug. Only one study (20), which evaluated the 
eﬀ ect of desipramide and escitalopram in PD patients, included a three factor model 
of the MADRS in the analysis. Both the “psychic anxiety/dysphoria” and “apathy/retar-
dation” factor as well as the” vegetative symptom” factor changed over a 30 day period, 
but there was no main eﬀ ect of time or treatment on any factor. Studies of the trajectory 
response in the primary psychiatric population are also sparse and show heterogeneous 
results.  Some studies report early improvement of anhedonia, sometimes as early as 
week one (21), whereas others showed early improvement of depression-related ideation 
followed by improvements in anxiety and somatisation (22). Possible explanations for 
these varying results are the heterogeneity of the studies, the confounding infl uences of 
placebo and the focus on individual item scores on the HAMD or MADRS instead of 
looking at domains consisting of grouped items.
Th e late improvement of depression-related ideation is in line with observations that 
depressive ideation and concentration diﬃ  culties in general seems to be one of the most 
frequent residual symptoms of major depression (23). 
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Knowledge of the diﬀ erent treatment response patterns can aid in patient counseling. 
Perceived lack of symptom relief is a primary reason of non-adherence or discontinua-
tion of treatment. For example, patients expecting a rapid relief of somatic symptoms 
(e.g., insomnia) may discontinue the treatment since they believe that they are receiving 
no benefi t from it (25). In addition, adverse eﬀ ects most frequent appear in the fi rst 
weeks, which lead to discontinuation of treatment in the fi rst 3 months in up to 40% of 
depressed patients in a psychiatric population (11). Reassuring of patients with expected 
outcome/response may promote patient compliance and may increase treatment eﬀ ect.
Th ere is a large and signifi cant, placebo eﬀ ect on all symptom domains, especially in the 
fi rst two weeks. After two weeks the placebo eﬀ ect on the aﬀ ective, somatic symptoms 
and cognitive symptoms seem to decline, with a trend of worsening towards week 12. 
Th e placebo eﬀ ect is a well-known phenomenon in depression studies, and may be res-
ponsible for improvement of up to 34% of depressive symptoms in PD patients (21,26). 
Since there seems to be a trend in diminishing placebo response between assessments at 
week 8 and 12, future studies should have a longer duration in order to better discrimi-
nate sustained response to active treatment from time-limited placebo response. 
Th is study has several limitations. First of all, the sample size is small and, in addition, 
19% of randomized patients could not be included because they withdrew or had some 
missing data. In order to increase the power we decided to combine the paroxetine 
and venlafaxine groups. Although the mechanism of action diﬀ ers between the two 
treatments (one is an selective serotonin reuptake inhibitor and the other a serotonin 
and noradrenalin reuptake inhibitor) we speculate that their treatment eﬀ ects would be 
comparable in this population (12). An exploratory post-hoc analysis of paroxetine or 
venlafaxine alone versus placebo showed response patterns similar to our primary ana-
lysis. Recent papers identifi ed individual trajectories of recovery of depressed patients 
in a primary psychiatric population using growth mixture modelling (GMM) (27,28). 
GMM has the advantage that it allows for diﬀ erent treatment eﬀ ects in diﬀ erent trajec-
tories classes, so that fundamentally diﬀ erent trajectories shapes can be detected. Ho-
wever, GMM also requires a larger sample sizes than available in the SAD-PD database. 
Th is is why we decided to use the repeated measurement model to detect trajectory 
“shape” response pattern over time. Last, we based our symptom domains on face va-
lidity since the factor analyses of the scales are unsatisfactory (19). In order to increase 
the stability of these domains and the likelihood of identifying diﬀ erent trajectories we 
included diﬀ erent depression scales. In addition, items of the three scales overlap, which 
we believe strengthened the diﬀ erentiation between aﬀ ective, cognitive and somatic tra-
jectories of recovery.
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CONCLUSIONS
In this study, aﬀ ective symptoms showed the earliest treatment eﬀ ect in depressed PD 
patients treated with paroxetine or venlafaxine, followed by somatic symptoms and last 
cognitive/ideational symptoms. A more thorough understanding of the treatment res-
ponse patterns may facilitate patient counseling with regard to treatment expectations, 
which may lead to improved medication adherence and hopefully a better treatment 
outcome. Another important conclusion is that our analysis underlines the importance 
of a suﬃ  ciently long study period in future studies, preferable longer than 12 weeks, 
in order to be able to separate persistent response to active treatment and time-limited 
placebo response.
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SUPPLEMENTARY FILES
Supplementary table 1. 
Baseline demographic and clinical characteristics of the active treatment and the placebo treated group.a
Variable Treatment group
(N=61)
Placebo group
(N=32)
Age (years) 64.2 (10.0) 61.4 (10.0)
Male (%) 62% 59%
Years since PD diagnosis 5.3 (4.1) 5.5 (3.9)
UPDRS total score 42.6 (17.5) 41.3 (16.4)
Major depression (%) 59% 56%
HAM-D total score 17.1 (4.3) 17.3 (3.8)
MADRS total score 20.1 (7.5) 20.2 (6.2)
BDI-II total score 16.7 (8.3) 17.8 (7.8)
UPDRS section 3 score 27.3 (11.1) 25.8 (11.9)
MMSE total score 28.9 (1.5) 28.6 (3.9)
Abbreviations: HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; 
BDI-II, Beck Depression Inventory II; UPDRS, Uniﬁ ed Parkinson’s Disease Rating Scale; MMSE, Mini Mental State 
Examination.
a Values are presented as mean (standard deviation) unless otherwise indicated.
Supplementary table 2. 
Mean z-scores and p value for the comparison between the active treatment (venlafaxine and paroxetine) and the 
placebo treated group in the affective, somatic and cognitive domain.
Domain
0
Week
2 4 6 8 12
Aﬀ ective
Z-score placebo 0.22 -0.624 -0.756 -0.981 -1.114 -0.865
Z-score treatment -0.13 -0.708 -1.212 -1.406 -1.575 -1.581
p 0.85 0.69 0.02 0.03 0.02 0.00
Somatic
Z-score placebo 0.071 -0.392 -0.477 -0.495 -0.673 -0.427
Z-score treatment -0.036 -0.393 -0.644 -0.841 -0.905 -0.951
p 0.55 0.99 0.33 0.04 0.10 0.00
Cognitive
Z-score placebo 0.025 -0.629 -0.702 -0.883 -0.822 -0.764
Z-score treatment -0.014 -0.618 -0.927 -1.088 -1.324 -1.28
p 0.82 0.95 0.16 0.16 0.00 0.00
P<.05 are shown in bold.  
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Supplementary table 3. 
Mean z-scores comparison between the placebo group (n=32), paroxetine group (n=33) and venlafaxine group 
(n=28). 
Affective domain:
Week Placebo Paroxetine Venlafaxine
0 .022 .105 -.151
2 -.624 -.631 -.798
4 -.756 -1.246* -1.173*
6 -.981 -1.372 -1.446*
8 -1.145 -1.639* -1.499*
12 -.865 -1.687* -1.455*
* p<.05 compared to placebo
Somatic domain:
Week Placebo Paroxetine Venlafaxine
0 .071 .073 -.165
2 -.391 -.341 -.454
4 -.477 -.629 -.661
6 -.495 -.798 -.891*
8 -.673 -.941 -.863
12 -.427 -.999* -.894*
* p<.05 compared to placebo
Cognitive domain:
Week Placebo Paroxetine Venlafaxine
0 .025 .047 -.086
2 -.629 -.519 -.735
4 -.702 -.849 -1.019
6 -.883 -1.079 -1.099
8 -.822 -1.300* -1.352*
12 -.764 -1.358* -1.188*
* p<.05 compared to placebo
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Unraveling the Relationship between Motor Symptoms, 
Affective States and Contextual Factors in Parkinson’s Disease: 
A Feasibility Study of the Experience Sampling Method
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ABSTRACT
Background: 
In Parkinson's disease (PD), the complex relationship between motor symptoms, aﬀ ec-
tive states, and contextual factors remains to be elucidated. Th e Experience Sampling 
Method provides (ESM) a novel approach to this issue. Using a mobile device with 
a special purpose application (app), motor symptoms, aﬀ ective states and contextual 
factors are assessed repeatedly at random moments in the fl ow of daily life, yielding an 
intensive time series of symptoms and experience. Th e aim of this study was to study the 
feasibility of this method. 
Method: 
We studied the feasibility of a fi ve-day period of ESM in PD and its ability to objectify 
diurnal fl uctuations in motor symptom severity and their relation with aﬀ ect and con-
textual factors in fi ve PD patients with motor fl uctuations. 
Results: 
Participants achieved a high compliance, with 84% of assessment moments comple-
ted without disturbance of daily activities. Th e utility of the device was rated 8 on a 
10-point scale. We were able to capture extensive diurnal fl uctuations that were not 
revealed by routine clinical assessment. In addition, we were able to detect clinically 
relevant associations between motor symptoms, emotional fl uctuations and contextual 
factors at an intra-individual level. 
Conclusions: 
ESM represents a viable and novel approach to elucidate relationships between motor 
symptoms, aﬀ ective states and contextual factors at the level of individual subjects. ESM 
holds promise for clinical practice and scientifi c research. 
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INTRODUCTION
Parkinson disease is a complex neurodegenerative disease with both motor and nonmo-
tor symptoms. In time, most patients with Parkinson's disease (PD) eventually develop 
motor fl uctuations such as “wearing-oﬀ ” and “on-oﬀ ” fl uctuations. It has been estimated 
that two thirds of these patients also experience mood fl uctuations (1, 2) and that these 
fl uctuations are often more disabling and distressing to patients than motor symptoms 
(3). Moreover, it is increasingly recognized that personal circumstances and contextual 
factors may also impact the severity of motor symptoms as well as the well-being of PD 
patients. However, the relationship between aﬀ ect, motor fl uctuations and their social 
context remains to be elucidated (4). Traditional research methods are unlikely to provi-
de suﬃ  ciently detailed and personal information to provide insight into the relationship 
between these variables. Assessing subjects several times a day during their normal daily 
activities, which is possible with the Experience Sampling Method (ESM), may not only 
provide information about the frequency and severity of emotions or motor fl uctuati-
ons, but also provide valuable information on situational and behavioural moderators 
driving these fl uctuations (5-8). 
Th e ESM approach is gaining terrain in the study of psychopathology, (5, 6, 9, 10) and 
is previously used among others, in studies on depression (11), asthma (12), irritable 
bowel syndrome (13) and migraine (14). To date, this approach had not yet been used in 
a PD population. Th e well known, but complex relation between the severity of motor 
symptoms in PD with aﬀ ect and contextual factors, varying during the course of the 
disease, represents a particularly good target for ESM. Th e method assesses symptoms, 
contextual factors and other variables several times a day at random intervals in the 
subject’s natural environment (5, 6). Th e primary aim of this study was to assess the 
feasibility of ESM in PD. In addition, we present an overview of the utility of ESM in 5 
PD patients with motor fl uctuations for detecting intra-individual associations between 
motor fl uctuations, aﬀ ective states and contextual factors. 
METHODS
Participants
Th is study was part of a clinical initiative to assess the feasibility of ESM for routine 
outcome monitoring in a psychiatric outpatient population (9). Th e parent study was 
exempt from ethical approval since it concerns routine clinical follow-up measurements. 
For our pilot study fi ve consecutive PD patients with motor fl uctuations from the mul-
tidisciplinary movement disorder clinic were asked to participate in this initiative to 
assess the feasibility of the ESM method to detect intra-individual fl uctuations. PD 
was diagnosed according to the Queens Square Brain Bank criteria (15). Subjects with 
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known cognitive impairment, operationalized as an MMSE <24, were excluded given 
anticipated diﬃ  culties in working with the mobile ESM application (PsyMate device). 
All approached subjects gave written informed consent. Th e parent study was approved 
by the Institutional Review Board of Maastricht University Medical Center. 
The Experience Sampling Method (ESM)
ESM is based on multiple repeated (within-subject) mini-measurements of experience 
(motor symptoms, anxiety, aﬀ ect, wellbeing, motivation, stress) and context (medicati-
on use, stressors, situations, activities) at unselected semi-random moments in daily life. 
Within-subject data provide subjects and health professionals with the opportunity to 
follow intra-individual changes in relation to in-the-moment daily life situations and 
experiences. As it assesses the occurrence of motor symptoms, mental states and contexts 
in the fl ow of daily life, ESM Is a validated, structured diary technique to assess subjects 
in their daily living environment (5, 16). ESM is able to follow the impact of motor and 
mental states, as well as their context, on each other over time. 
Measures
Th e PsyMate device used in this study (17) was an iPod touch with a special ESM 
app installed. Th e device is programmed to generate 10 beeps per day at semi-random 
moments in 90-minutes time blocks between 7:30 and 22.30, for 5 consecutive days 
(total of 50 measurement points). At each beep, the PsyMate presents a number of 
questions on the experience of motor symptoms, aﬀ ective states and contextual factors, 
which are recorded through a touch screen (Fig 1, screenshot question). First, subjects 
were asked if they felt in their “on” or “oﬀ ” state, the latter being a state where in their 
opinion the dopaminergic medication was not working anymore (due to the short half-
time of levodopa preparations). For example, when just before the next medication gift 
the subject experienced more motor- (return of parkinsonism), sensory- or autonomic 
symptoms, they answered they were in an “oﬀ ” state. On the contrary, when subjects 
experienced few complaints during dopaminergic treatment, they answered “on”. We 
included 5 Parkinson-specifi c questions, rating the symptoms ‘tremor’, ‘rigidity’, ‘pro-
blems with walking’, ‘balance problems’ and ‘dyskinesia’. Th ese questions were selected 
from the Unifi ed Parkinson Disease Rating Scale (UPDRS), which is a commonly used 
scale in PD (18). Since this was a pilot study we only included general motor symptoms 
and not more specifi c motor symptoms such as freezing, which is only present in a small 
proportion of PD patients. All of the included motor symptoms are strongly correlated 
with quality of life (19). To assess aﬀ ect state we used a constructed composite score for 
positive aﬀ ect (PA) and negative aﬀ ect (NA) (11), in line with previous studies (20, 21). 
PA comprised the weighted average of scores on the aﬀ ect adjectives: ‘happy’, ‘satisfi ed’, 
‘relaxed’ and ‘feeling well’ and for NA: ‘insecure’, ‘lonely’, ‘anxious’, ‘irritated’, ‘guilty’, 
‘suspicious’ and ‘threatened’. As contextual factors, the whereabouts, presence of others, 
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and activities of the subject were registered, as well as how comfortable the subject felt 
in these circumstances.  All PD symptoms and aﬀ ect adjectives were rated by subjects on 
a 7-point Likert scale ranging from 1 = ‘not at all’ to 7 = ‘very’.  A complete overview of 
the questions is given in supplementary S1 table A. Th e questions were the same for each 
measurement point. In addition, once in the morning and once in the evening, subjects 
had to fi ll in additional ‘morning’ and ‘evening’ questionnaires (S1 table B). Th e appli-
cation uploaded the responses in an anonymized central database, from which they were 
analyzed. Th e data collection method can be considered ecologically valid measures of 
the subject’s circumstances and aﬀ ective fl uctuations in the fl ow of daily life (5, 6, 22).
Figure 1. 
Screenshot of the question “Ik voel me opgewekt“ (“I feel cheerful”) on a 7 point Likert scale. A score of 1 indicates 
“niet” (“not at all”), a score of 4 “matig” (“moderate”) and a score of 7 “Zeer” (“Very much so”).
Assessment 
Baseline demographic and disease-related characteristics were collected during a visit at 
the outpatient clinic (MPGB). In addition, the following scales were applied: the Hoehn 
and Yahr stage (23), the UPDRS to quantify motor symptoms, the Mini-Mental State 
Examination (MMSE) to assess global cognitive function (24), the Beck Depression 
Inventory II (BDI-II) to assess depressive symptoms (25), the Parkinson Anxiety Sca-
le (PAS) (26) to assess anxiety symptoms and the Parkinson Disease Questionnaire-8 
(PDQ-8) (27) to assess quality of life. During the assessment subjects received oral 
information on how to interpret the question about the “on” or “oﬀ ” state. On the same 
day, information about the PsyMate as well as a demonstration was given in person 
(VAM). Subjects were given the option to either download and use the PsyMate on their 
own smartphone (iOS or Android), or to use an iPod touch provided by Maastricht 
University Medical Centre for the duration of the study. During the following fi ve con-
Chapter 6
102
secutive days the PsyMate generated a total of 50 semi-random measurement points, 10 per 
day. At day two, subjects were called to check whether everything was clear and functioning 
correctly. At any time during the study period, subjects could ask for help by calling one of 
the investigators (VAM). After fi ve days, they returned the device and the data were collec-
ted in an anonymized central database. Two weeks later, the subjects were interviewed by 
telephone about their experiences with the device (see S1 table C for evaluation questions).
Statistical analysis
Before running the analysis, missing items due to technical issues of the device were ex-
cluded from the data set. First, descriptive statistics were calculated for all PD symptom 
variables, as well as PA and NA. Since all variables were not normally distributed (kur-
tosis values ranging from 2.9 to 28.7), correlations were computed with Spearman’s rho. 
Strength of the correlation was defi ned as r < 0.3 very small, r = 0.3-0.5 small, r = 0.5-0.7 
moderate and r  > 0.7 strong. Additionally, eﬀ ect sizes were calculated by calculating Co-
hen’s d, e.g. a 1 point change on the scale has an eﬀ ect size of 1/standard deviation of the 
variable. Strength of the eﬀ ect size was defi ned as medium d = 0.3-0.6 and large d > 0.6. 
Analyses were done using the statistical software program STATA (version 13.1 for Mac).
RESULTS
Table 1 shows baseline characteristics of the 5 subjects. Th e mean age was 60.4yr (SD 
6.1). All subjects had a Hoehn and Yahr stage of 2-2.5, which indicates bilateral or mid-
line involvement of the disease, without impairment of balance or a recovery on the pull 
test. Th e mean UPDRS III score was 22 (SD 6.2). On the PAS, subject 1 and 4 scored 
above the cut-oﬀ  point of 13/14 indicating clinically relevant anxiety. Subject 4 also 
scored above the cut oﬀ  score of 14/15 on the BDI-II, which fi ts with a mild depression. 
Quality of life of the subjects was relatively good with a maximum score of 13 out of 32, 
with higher scores indicating a lesser quality of life. 
Compliance
A mean total of 84% (range 76-96%) of all 50 measurement points were completed cor-
rectly. Previous research has shown that ESM data validity is compromised if less than one 
third of beeps yield data (5). All subjects in met this requirement. Subject 2 and 3 both 
missed three beeps because they did not hear the sound of the alarm and subject 4 went 
swimming several times and missed four beeps when she was in the water. Unfortunately, 
when transferring data from the device of subject 1, data of fi fteen measurement points 
were lost due to connection malfunction. Th e exact cause of this malfunction remains un-
clear. Th ere was no signifi cant diﬀ erence in terms of compliance between the three subjects 
using their own smartphone and the two using an Ipod (89% vs 83%).
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User friendliness, evaluation and feedback
All subjects found the information about the PsyMate device clear and concise. None of 
them said they changed their daily behaviour. Th is occasionally led to a missed assessment 
point when they were showering, swimming, riding a bike or driving a car. Th ree subjects 
used their own smartphone and two used an iPod. Th ese two were not inconvenienced by 
having to carry the iPod device with them. Beep assessments never took more than 5 minu-
tes, with a mean completion time between 2 and 3 minutes. Th e mean utility score that the 
subjects gave the device was 8 on a 10-point scale. Some subjects suggested also including 
questions about exercise, since in their own experience this also infl uences their aﬀ ect. Th ree 
subjects mentioned that repetitive assessments tended to get boring. However, studying the 
relationship between aﬀ ect and motor fl uctuations and contextual factors was considered 
very meaningful by all subjects and they all would participate in future ESM studies.
Ability to detect diurnal ﬂ uctuations in motor symptom severity at an 
individual level.
Fig 2 shows the overall motor symptom severity and the real-time diurnal fl uctuations 
in motor symptom severity of subject 4. Cohen’s d for tremor was .75 and 1.28 for PA, 
with indicates a large, meaningful eﬀ ect size of a 1 point change on the Likert scale. 
Similar patterns were found in all subjects. Th ese fi gures show that ESM is sensitive 
enough to capture clinically relevant diurnal fl uctuations of motor symptom severity.
Ability to detect intra-individual relationships between motor symptoms, 
affect and contextual factors in 5 PD subjects with motor ﬂ uctuations
First, since subjects with mood fl uctuations are more likely to have higher scores on psy-
chiatric rating scales [28], we expected that subjects 1 and 4, which had the highest sco-
res on the anxiety and depression rating scales, would also have the strongest correlation 
between motor symptoms, aﬀ ect and possibly contextual factors. Th is was especially 
true for the severity of the tremor; both subject 1 and 4 had a moderate negative correla-
tion between positive aﬀ ect and the severity of the tremor (r=-0.5, p<.01). For subject 1, 
Cohen’s d for tremor was .57 and 2.63 for PA, indicating a large eﬀ ect size for a 1-point 
change on the Likert scale.  See Figs 3 and 4 for an example of the fl uctuations of tremor 
and aﬀ ect during the day. In Fig 3, one can see that the severity of the tremor fl uctuates 
heavy, but the positive aﬀ ect line shows only minor changes. Th is is most likely because 
the PA is a weighted average of 4 aﬀ ect adjectives and when looking closer at the data 
it turned out that mainly the variable “satisfi ed” had a correlation with tremor (r=-0.6, 
p<.01). In subject 4, feeling relaxed (r=-0.6, p<.01), satisfi ed (r=-0.6, p<.01) and feeling 
happy (r=-0.4, p<.01) all had a negative correlation with tremor severity, visible as a 
more fl uctuating PA pattern in the diagram.  On the contrary, subject 5 had the lowest 
scores on the rating scales and we were unable to fi nd a signifi cant correlation between 
aﬀ ect and any of the motor or contextual factors.
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Figure 2a and 2b. 
Cross-sectional overall daily assessment (Fig 2a) versus real-time measurements (Fig 2b) of motor symptoms in 
subject 4.
 
 
Legend: Y-axis: item score (1= not all, 7 = very much); X-axis: time. Blue solid line: Tremor; Orange line: Dyskinesia; 
Red line: Trouble Walking; Green line: Rigidity.
Figure 3. 
Example of real time assessment of tremor and positive affect in subject 1.
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Figure 4. 
Example of real time assessment of tremor and positive affect in subject 4.
Second, we evaluated the infl uence of context on the severity of motor symptoms. Again, 
in subject 1, the eﬀ ect was most impressive. Fig 5 shows that all motor symptoms were 
more severe when he was not at home but in public. In the other subjects it was diﬃ  cult 
to fi nd a correlation between contextual factors and symptom severity, mainly because 
the measurement point were not evenly distributed, e.g. most of the measurements were 
taken at home, or in company with their spouses with only a few measurements taken 
in the opposite situation which makes a statistical comparison diﬃ  cult.  
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Figure 5. 
Clustered column diagram of motor symptom severity in subject 1. 
Legend: Y-axis: item score (1= not all, 7 = very much); X-axis: motor symptoms.
Th ird, to test whether individual motor symptoms were logically correlated, e.g. im-
proved rigidity will normally lead to impaired balance or walking diﬃ  culties, we cal-
culated these correlations in subject 3, who had a moderate score on the UPDRS III. 
We found a strong correlation between rigidity and the severity of walking diﬃ  cul-
ties (r=0.8, p<.01). Balance problems were moderate correlated with dyskinesia (r=0.6, 
p<.01) and also strongly correlated with walking diﬃ  culties (r=0.8, p<.01). For subject 
3 Cohen’s d for balance problems was 1.90, for walking diﬃ  culties 1.26 and 3.51 for 
dyskinesia.  Similar correlation coeﬃ  cients were found in the other subjects, which in-
dicated that their symptoms were logically scored. 
Last, we tried to detect eﬀ ects of dopaminergic treatment on the motor symptoms or 
aﬀ ect fl uctuations. However, in this pilot application subjects were not asked to mark 
at what exact time they took their medication, so we were only able to visible link their 
prescription time with the severity of their symptoms. For example, according to her 
prescription time subject 4 took levodopa medication at 7 and 11 o’clock in the morn-
ing, three o’clock in the afternoon and 7 and ten o’clock in the evening. Looking at her 
severity of the tremor (Fig 4), it seems that the tremor was worse just before she took her 
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medication (point 3, 10:56) and less severe just after her medication (point 6, 15:08). 
Since the tremor severity and positive aﬀ ect were correlated, this was also true for her 
aﬀ ective state, having a more positive aﬀ ect just after the medication gift. However, we 
realize this is not very accurate, since actual medication times can diﬀ er notoriously 
from prescription times.  
DISCUSSION
Th is pilot study shows that ESM is a viable and promising method for evaluating aﬀ ect 
and motor fl uctuations in relation to contextual factors in PD. Subjects achieved a high 
compliance rate without disturbance of normal daily activities. Th e average rating of the 
utility of the device was an 8 on a 10-point scale. Subjects were confi dent that ESM had 
the potential of revealing meaningful information of factors associated with fl uctuations 
in motor symptom severity. ESM proved to be sensitive enough to capture extensive 
diurnal fl uctuations in motor symptom severity, aﬀ ective states and contextual factors. 
Th e advantage of ESM is that assessments take place in the fl ow of daily life, in the natural 
environment of the subject. Th is is important since contextual factors play an important 
role in motor symptom severity, aﬀ ect and behavior (29, 30). By assessing subjects during 
normal activities in their natural environments, ESM avoids some of the methodological 
problems commonly encountered in research, which has implications for treatment. First, 
it reduces recall bias. Current assessments in clinical settings often rely on retrospective 
questionnaires and this possible leads to several sources of recall bias. It has been shown in 
depressed subjects that there is a high discrepancy between retrospective ratings and actual 
experiences (31). Another advantage is that by using an electronic device, investigators 
can be confi dent that the ratings were actually completed at the time specifi ed by the rese-
arch design, which one cannot be sure of when using repeated paper questionnaires. Th is 
avoids the problem of “back-fi lling” the diaries when subjects neglect to make ratings at 
the scheduled time. A clinical advantage of the ESM approach is that multiple repeated as-
sessments within each subject, forming an intensive time series of symptoms, context and 
experience, increases the power of the data to such an extent that analysis of single subject 
time series becomes possible. Th is enables the recognition of highly individual patterns 
of reactivity to contextual factors, and may facilitate the prediction of ‘oﬀ ’-periods and 
other important transitions (32). Person-specifi c patterns may be fed back to the subject 
to enhance insight into factors associated with symptom severity and facilitate self-ma-
nagement. Behavioural insight may enhance feelings of mastery over the symptoms, and 
facilitate coping or adjustment of activities. Providing feedback may also lead to an incre-
ased sense of involvement in treatment, better adherence and better treatment outcome, 
as was previously reported in other subject populations, such as subjects with depression, 
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migraine and asthma (33-35). 
Th e monitoring of treatment progress is also a promising clinical application. ESM 
may reveal relatively small treatment eﬀ ects by avoiding clouding due to recall bias 
when using retrospective self-report measures (36). Th is would allow for more targe-
ted and individualized pharmacotherapy. A practical advantage is that ESM software is 
freeware and can be downloaded for free as an app on smart phones or iPods. 
A possible limitation of ESM used in our study is that it needs a certain level of motor 
function to use the telephone device but also a suﬃ  cient cognitive level to understand 
the information and learn to use the PsyMate program. For this reason, the use of ESM 
is limited to a selected population with suﬃ  cient cognitive and motor function, which 
in future studies could lead to selection and lack of generalizability. However, in most 
PD studies a certain level of cognitive function is already required. Second, the presence 
of motor fl uctuations was based on self-reports, i.e. were not observer-rated, which may 
diﬀ er objective ratings of fl uctuations. Previous studies on motor and mood fl uctuations 
reported a discrepancy between self-reported and physician-documented motor fl uctu-
ations, which could be due to “over reporting” of fl uctuations by subjects but also by 
the tendency of neurologists to continue to view subjects who have developed motor 
fl uctuations as “fl uctuators”, regardless of how well controlled their symptoms are at 
a given time (28). Such overestimation of fl uctuations could be a problem, especially 
when treatment modifi cations are made due to ESM results. To further objectify the 
motor fl uctuations additional use of an accelerometer is a possible solution, a method 
that is currently fi nding its way in studies of movement and gait disorders in PD (37, 
38). With respect to the overestimation of emotional fl uctuations, previous research 
has shown that self-reports are an useful source of data when dealing with immediate 
experiences such as aﬀ ective states (16, 39). In our study it seems that the self-reports 
on emotional items are plausible representations of reality. However, this needs to be 
validated further. Last, our study was part of a larger study on ESM in a psychiatric po-
pulation. Further studies are needed to validate our preliminary fi ndings on the ability 
of ESM to detect meaningful intra-individual relationships. Th ese future studies should 
implement an ESM questionnaire optimized for PD patients, e.g. more questions about 
motor symptoms and a more precise medication time queue which enables researches to 
better detect medication infl uences. In addition, PD patients with diﬀ erent stages of the 
disease should be included, to extend our fi ndings in subjects who are more disabled. 
However, taken all these limitations into account, we think that ESM is a feasible me-
thod in PD and holds promises for future scientifi c and clinical implications.
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CONCLUSION
ESM may be a viable and useful method in PD. Subjects reached a high complian-
ce rate and were able to rate multiple symptoms simultaneously in a brief period of 
time, without disturbance of daily activities. Th e study shows that ESM technology is 
sensitive enough to capture extensive diurnal fl uctuations of motor symptom severity, 
aﬀ ective states and contextual factors in individual subjects. Th erefore ESM could be a 
useful tool for fi ne grained analyses of how these variables impact each other in the fl ow 
of daily life in individual subjects, and how these patterns may be altered as a function of 
treatment. Detailed feedback to the subject may enhance insight and facilitate self-ma-
nagement, shared decision making and compliance. 
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SUPPLEMENTARY FILES
S1 table A. 
Experience Sampling Methods protocol, question per beep. 
Domain Item Description Score
Mood 1 I feel happy 1-7 (1=not, 4=moderate, 7= very)
2 I feel insecure 1-7
3 I feel relaxed 1-7
4 I feel irritated 1-7
5 I feel satisfi ed 1-7
6 I feel lonely 1-7
7 I feel afraid 1-7
8 I feel down 1-7
9 I feel guilty 1-7
10 I rack my brain 1-7
11 I feel suspicious 1-7
12 I feel threatened 1-7
13 Currently I am: 1=”on”, 0=”oﬀ ”
Parkinson 14 I experience tremor 1-7
15 I experience rigidity 1-7
16 Walking is diﬃ  cult 1-7
17 I experience balance problems 1-7
18 I experience dyskinesia 1-7
19 Personal complaints: Open question
20 In general, I feel well 1-7
Context 21 Currently I am: Resting/working/housework/hygiene/
eating,drinking/relaxing/conversating/other 
22 I rather do something else 1-7
23 Where am I? Home/work/ friends place/public place/on the go
24 With who am I? Partner/family/friends/collegues/nobody
25 I fi nd this pleasant 1-7
Somatic 26 I am hungry 1-7
27 Since the last beep I used: Nothing/caﬀ eine/nicotine/alcohol/medication/cannabis/food/other
28 I am tired 1-7
29 I am not feeling well 1-7
30 I have pain 1-7
31 I experience: Headache/abdominal pain/breathing diﬃ  culties/muscle 
ache/ obstipation/tinnitus/dizziness/ dyspnea/ palpita-
tions/incontinence
Events 32 Th e most important event since 
the last beep was:
Open question
33a Th e event was: -3 = very displeasing, 0 = neutral , 3 = very pleasant 
33b Th e event was: -3 = not important, 0 = neutral, 3 = very important
33c Th e event was under my control 1-7
33d I expected this event 1-7
34 Th is beep was unpleasant 1-7 
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S1Table B. 
Additional questions once in the evening and once in the morning.
Item Scale
EVENING
In general, I felt well today 1-7 (1=not, 4=moderate, 7= very)
In general, I felt tired today 1-7
In general, I felt tense today 1-7
In general, I puzzled over a lot today 1-7
Today, I experienced Parkinson symptoms 1-7
Today, I experienced  headache 1-7
Today, I experienced stomachache 1-7
Today, I had diﬃ  culties breathing 1-7
Today, I had muscle pain 1-7
Today, I experienced obstipation 1-7
Today, I experienced tinnitus 1-7
Today, I experienced palpitations 1-7
I was dizzy today 1-7
I had dyspnea today 1-7
I experienced micturition problems 1-7
Filling in these questions infl uenced my mood 1-7
Without PsyMate, I would have done diﬀ erent things today 1-7
MORNING
How long did it take to fell asleep yesterday? 0-5min/5-15min/15-30min/30-45min/45min-1h/ 
1-2h/2-4h/>4h
How many times did I wake up last night? 0- >5 times
How long was I awake this morning, before I got up? 0-5min/ 5-15min/15-30min/30-45min/45min-1h/ 
1-2h/2-4h/ >4h
I slept well 1-7
I feel fi t 1-7
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S1 Table C. 
Evaluation questions asked during telephone interview.
1.  Was the goal of our study clear to you?
2.  Was the information about the study clear and suﬃ  cient for you?
3.  Were all the question clear? If not, which questions were not clear?
4.  Did you change your daily behavior during the study period? If so, why?
5. Did you bother caring around the PsyMate device (or cell phone) all day long?
6.   Did you miss any measurement points? If so, how many and why (for example: I did not hear the beep/
forgotten/embarrassment)?
7.  Did you fi ll in the questions by yourself or with your partner?
8.  Please give an overall score for the utility of the device and program (0-10)?
9.   How long did it take to fi ll in one measurement point (0-1min, 1-2min, 2-5min, >5min)?
10.  Do you have any suggestions or comments to improve the study design?  
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Chapter 7
GENERAL DISCUSSION
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Th e main aim of this thesis was to investigate conceptual and clinical aspects of anxiety 
and depression in Parkinson’s disease, alongside testing the feasibility of a new method 
to further unravel the complexity of these non-motor symptoms in the future.  In the 
fi rst part of this chapter methodological issues of our studies are assessed. In the second 
part, the implication of our fi ndings on the concept and classifi cation of anxiety and de-
pression in PD are discussed and some recommendations for future research are given.
1.  METHODOLOGICAL CONSIDERATIONS
1.1 Study populations
Two out of fi ve studies presented in this thesis involved patients from a cross-sectional 
multicenter study on anxiety disorders in PD conducted in 2008 and 2009 (Chapter 3 
and 4) (1). Patients were recruited from consecutive referrals to movement disorder cli-
nics, neurology clinics and psychiatry clinics of six centers in the United States, Europe 
and Australia. One study (Chapter 5) involved data from the Study of Antidepressants 
in PD (SAD-PD) (2), a study on the eﬃ  cacy of treatment with venlafaxine or paroxetine 
over placebo treatment in depressed PD patients. It involved 20 centers in the United 
States, Canada and Puerto Rico from 2005 through 2009. Th e pilot study testing the 
feasibility of the Experience Sampling Method (ESM) was part of a larger study in a psy-
chiatric population and enrolled 5 consecutive PD patients from the multidisciplinary 
movement disorder clinic of Maastricht University Medical Center (Chapter 6).  Of 
the patients studied in chapter 3 and 4, 61% were male with a mean age of 64.8 years 
and disease duration of 8.3 years. Mean UPDRS motor score was 26.4 points. Th ese 
characteristics are comparable to the patients included in chapter 5, in which 61% were 
male, the mean age was 63.2 years and the mean UPDRS motor score was 28.8. Disease 
duration was shorter, with a mean of 5.4 years. In our pilot study, four out of fi ve parti-
cipants were male; the mean age was 60.4 years and the mean disease duration 8 years. 
Th e UPDRS III motor score was 22 points.  Overall, patients included in our studies 
had a mean Hoehn and Yahr rating of 2-2.5, indicating bilateral or midline involvement 
of the disease without impairment of balance or a recovery on the pull test. Comparing 
study characteristics to other large studies in the fi eld (3, 4), we see that demographic 
and disease related characteristics are comparable. Th erefore, we think that our results 
are generalizable to a population that clinicians encounter in outpatient clinics. Alt-
hough most studies were multicenter studies, no Asian or African centers participated. 
As shown in Chapter 1, anxiety is more common in western developed countries (5), 
which could implicate that our fi ndings are not generalizable to Asian or African coun-
tries. Second, since most patients were recruited from movement disorder clinics, a pos-
sible infl uence of recruitment bias cannot be ruled out. Tertiary centers may encounter 
more complex patients with a higher prevalence of anxiety or depression.  
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1.2 Diagnostics and rating scales
In all studies, the diagnosis of idiopathic PD was made based on the clinical Queen 
Square Brain Bank criteria (6). Patients with neurodegenerative disorders other than PD 
and patients who had undergone DBS were excluded.  In chapter 2 and 3 anxiety disor-
ders were classifi ed according to DSM-IV criteria, currently the most used classifi cation 
system for anxiety disorders (7). However, due to high comorbidity rates its validity in 
the general population is questioned (8-10) and since we found that up to one third 
of PD patients diagnosed with anxiety also experienced multiple anxiety disorders, it 
appears that the construct validity of the current DSM classifi cation is also questionable 
in PD patients (Chapter 2).  On the contrary, diagnosing depressive disorders in PD 
with DSM-IV criteria seems appropriate in PD (11), although the National Institute of 
Neurological Disorders and Stroke (NINDS) (12) suggest some minor changes. Th ese 
include 1) Assessment based on an “inclusive” approach, rather than the “etiologic” 
approach recommended by DSM, 2) Elimination of the DSM exclusion criterion “due 
to the eﬀ ects of a general medical condition”, 3) a modifi cation of the anhedonia/loss 
of interest criterion to distinguish from primary apathy and 4) conduction of evaluati-
ons with awareness of whether the mood disturbance is related to motor fl uctuations. 
Establishing true prevalence and severity of anxiety and depression in PD remains a 
diagnostic challenge because of the symptomatic overlap between the somatic features 
and the neuropsychiatric features of PD.  Since, valid depression scales are important 
for adequate recognition and subsequent treatment, we assessed in chapter 4 the factor 
structure of the most commonly used measure of depressive symptoms in PD: Th e 
Hamilton Depression Rating Scale (HAMD). It appears that, although other clino-
metric properties of the scale are satisfactory, the factor structure is not. Th is makes it 
appropriate as a screening and evaluating tool, but not for studying specifi c symptom 
domains based on factorial structure in PD. Th erefore, in chapter 5 we based our symp-
tom domains on face validity instead of factor structure. Th e symptoms of the HAMD, 
Montgomery-Asberg Depression Rating Scale (MADRS) and the Beck Depression In-
ventory II (BDI-II) were combined and as such we believe that the symptom overlap 
of these scales strengthened the diﬀ erentiation between aﬀ ective, cognitive and somatic 
domains. With respect to the anxiety rating scales, it is well known that most anxiety 
scales are inappropriate to diagnose anxiety disorders in PD (13, 14). Some scales, such 
as the Beck Anxiety Inventory (BAI) focus mainly on symptoms of panic disorder while 
the Hamilton Anxiety Rating Scale (HARS) predominantly consists of items assessing 
generalized anxiety. In addition, the positive predictive values of most scales are sugge-
sted to be low in PD and consequently may contribute to a poor diagnostic accuracy 
(14). Preferably we would have used the recently developed and validated Parkinson 
Anxiety Scale for our model of anxiety in PD (Chapter 3), which better discriminates 
between episodic and persistent anxiety (15).  However, the scale was not yet available 
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during the study period. In our current model, the high correlation of the HAMD and 
the HARS may have introduced the problem of collinarity. However, the fact that only 
an acceptable model fi t was reached after including the HAMD variable and a model of 
depression showed a good fi t without including the HARS variable, suggests diﬀ eren-
tial explanatory values. Last, including items from the PAS into the ESM application 
(Chapter 6) could be useful to further unravel the association between motor symptoms 
and aﬀ ective states. 
1.3 Statistical approaches
In chapter 2 we conducted a systematic review of anxiety disorders in PD following 
PRISMA guidelines (16). We calculated a weighted point prevalence of the diﬀ erent 
anxiety disorders and clinically relevant anxiety symptoms assessed by rating scales. For 
creating a model of anxiety (Chapter 3) we performed structural equation modeling 
(SEM). Th is method aims to identify the most parsimonious model that accounts for a 
substantial part of the variance in the total anxiety score. A limitation of this method is 
that parameters selected to be included in the analyses are based on availability. Th ere-
fore some variables, such as personality, marital status or coping style were not included 
in our analysis. Including a wider range of variables would lead to a more complete psy-
chosomatic overview of all factors associated with anxiety in PD. In chapter 4 a principal 
component analysis was conducted on the HAMD. Subsequently, since the factor struc-
ture was unsatisfactory, we grouped items together into an aﬀ ective, somatic or cogni-
tive domain based on face validity to unravel trajectories of recovery in depressed PD 
patients (Chapter 5). In order to increase the stability of the domains and the likelihood 
of identifying diﬀ erent trajectories we included diﬀ erent depression scales. We examin-
ed domain diﬀ erences using a repeated measures analysis of variance (rm-ANOVA). 
Preferably we would have used growth mixture modeling (GMM) to identify diﬀ erent 
treatment eﬀ ects in diﬀ erent trajectory classes on an individual basis, but GMM requi-
res much larger sample sizes than were available in the SAD-PD database. In chapter 6 
we assessed the feasibility of the Experience Sampling Method (ESM) in 5 PD patients 
with motor fl uctuations. In addition, correlations between motor symptoms, contextual 
factors and aﬀ ective states were calculated. Since our primary aim was feasibility of the 
method and only two participants exhibited high scores on the anxiety and depression 
rating scales statistical analysis was limited. Further studies are needed to validate our 
preliminary fi ndings on the ability of ESM to detect meaningful intra-individual relati-
onships and the way these could be used on routine pharmacological treatment.
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2.  THE CONCEPT OF ANXIETY AND DEPRESSION IN PD 
2.1 Risk factor, prodromal symptom or psychological reaction?
A plausible explanation for the high prevalence of anxiety and depression in PD is that 
they are a psychological reaction to the impairments associated with disease progression. 
Invalidating and unpredictable motor symptoms lead to a perceived lack of control or 
embarrassment and in people with insuﬃ  cient coping mechanism this eventually leads 
to anxiety or depression. On the contrary, several mainly register based studies showed 
that PD patients are at greater risk of developing anxiety and depressive disorders al-
ready before the diagnosis of PD is made (17-23). Th ese studies suggest that anxiety and 
depression are a “pre-motor” manifestation of PD, related to neurobiological changes. 
Others have postulated a premorbid anxious personality as a risk factor for PD, which 
together with a high prevalence of anxiety disorders and depression among family mem-
bers of PD patients suggests a genetic predisposition (24, 25). However, no consensus 
about the attribution of genetic polymorphisms to anxiety and PD currently exists. 
Furthermore, anxiety and depression are more common in PD when compared to other 
illnesses suggesting a cause that is unique to PD (26, 27). Symptom overlap between 
depression, anxiety and Parkinson’s disease could point to a similar neurobiological ba-
sis. Everything taken together there appears to be a “late onset” anxiety or depression, 
which is related to a psychological reaction on the burden of the disease. Th is “late 
onset” type is most likely situational, related to oﬀ  periods and specifi c ADL activities, 
which we also found in our anxiety model (Chapter 3). Although not thorough studied 
yet, insuﬃ  cient coping mechanisms and psychological factors such as fear of falls, fu-
ture dependency and burdening of others may further elevate the (pre-existing) risk for 
anxiety. Th is pre-existing risk or vulnerability for anxiety or depression is most likely 
due to “early onset” neurobiological changes in dopaminergic as well as serotonergic and 
noradrenergic neurotransmitter systems (28, 29). Th e question whether these neurobio-
logical changes are a general risk factor for developing PD or if they are a prodromal 
symptom, e.g. part of PD symptomatology such as anosmia, remains a conundrum. 
In chapter 3 we proposed a model of anxiety in PD in which we showed than non-PD 
specifi c factors, such as a previous history of depression, are stronger markers for anxiety 
in PD than PD-specifi c risk factors such as motor fl uctuations. Th e same was found in a 
model of depression in PD (30). Confi rmation of these fi ndings in longitudinal studies 
would support the hypothesis that patients with a specifi c constellation of general risk 
factors for anxiety or depression could also predispose them to PD, which more point to 
a risk factor than a prodromal stage of the disease. 
2.2 Current classifi cation of depression and anxiety in PD
Th e majority of studies investigating depression and anxiety disorders in PD use the 
DSM classifi cation (7). Depressive disorders include major depressive disorder, dyst-
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hymic disorders and bipolar disorders. An extensive review found a prevalence of 17% 
major depressive disorders and 13% minor depression in PD (31). Given the relevance 
of depression in PD, valid diagnostic criteria are necessary. A study that assessed the va-
lidity of diagnostic DSM criteria for depression in PD concluded that DSM criteria are 
valid in PD for diagnosing major depression in clinical practice and research (11, 12). 
Anxiety is categorized into generalized anxiety disorder (GAD), panic disorder, ago-
raphobia, obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSS), 
social or specifi c phobia and anxiety not otherwise specifi ed (NOS). Some have ques-
tioned the validity of these criteria in anxious PD patients (1). First, our review on the 
prevalence of anxiety disorders in PD showed that approximately one third of patients 
diagnosed with anxiety experienced multiple anxiety disorders. It is plausible that this 
is an artifact of the current classifi cation system instead of a representation of true co-
morbidity of multiple distinguishable disorders (1). Second, a signifi cant proportion 
(Chapter 1, 13.3%) of patients have anxiety disturbances that do not meet the criteria 
for any specifi c anxiety disorder and are classifi ed as anxiety NOS. Th ird, there is a high 
co-occurrence of depression and anxiety in PD (26, 27, 32, 33), which is not accounted 
for in the current classifi cation system. As well as the high prevalence of anxiety NOS 
and the multiple anxiety disorders could explain the high variation of prevalence rates 
we found in our review. For example, some researchers used hierarchical DSM criteria 
and ruled out GAD if another current anxiety disorder was diagnosed, leading to a lower 
prevalence of specifi c anxiety disorders. 
2.3  Towards a new classifi cation of anxiety in PD
Taken the abovementioned considerations together, there is reason to question the con-
struct validity of the current DSM classifi cation for anxiety syndromes in PD patients. 
To this end, a new classifi cation is proposed using a data driven approach and latent 
class analysis. Starkstein et al. identifi ed two subgroups of anxiety in a sample of 342 PD 
patients (34). Th e fi rst group was termed “episodic anxiety” which included symptoms 
of panic disorder, agoraphobia and social phobia. Th e second group, “persistent anxie-
ty” included the essential symptoms of GAD. Intriguing, persistent anxiety was always 
associated with high probabilities for essential symptoms of major depression, whereas 
episodic anxiety was not. Other studies dividing episodic from persistent anxiety also 
found a strong association between depression and persistent anxiety (e.g. GAD) in PD 
(1, 33) and in the general population (8). Starkstein proposed a classifi cation into three 
classes: “episodic anxiety without depression”, “persistent anxiety with depression”, and 
“both persistent and episodic anxiety with depression”.  Th is is in concordance with 
our model of anxiety in which depression is the most important marker and also with 
a latent class analysis in 513 PD patients done by Brown et al. He found an “anxiety 
alone”,  “anxiety with depression” and “depression without signifi cant anxiety”- group 
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(35). Since he used rating scales to assess anxiety and depression instead of DSM criteria, 
no subdivision in episodic or persistent anxiety could be made. However, both studies 
suggest a diﬀ erent nosology in PD from the anxiety syndromes described in the DSM, 
with also a role of comorbid depression.
2.4  Motor and non-motor subtypes in Parkinson’s disease
Up until the nineties of the last century, Parkinson’s disease was considered a single 
entity, but during the past 2-3 decades the clinical heterogeneity has been recognized 
and several sub-classifi cations based on clinical features have been proposed (36-38). 
Some divided patients in benign or malignant, but one of the earliest and most used 
classifi cations categorized PD in two subtypes: a tremor dominant type (TD) and one 
with postural instability and gait diﬃ  culty (PIGD), also called the akinetic/rigid type 
(AR) (39). In the past years several others identifi ed PD phenotypes using a data driven 
approach with latent class analysis. Th is technique assesses the symptom profi le of indi-
vidual patients and produces classes of patients as suggested by their respective pattern 
of symptoms. Individual patients can only belong to one class (34). In general, four 
subtypes were identifi ed: 1) old age at onset and rapid disease progression, 2) tremor-do-
minant phenotype, 3) young onset PD with slow progression and 4) postural instability 
and gait diﬃ  culties (40). As one can see, some subtypes are related with rapid disease 
progression, whereas others are associated with relatively slow disease progression and 
lower mortality rates (41, 42), which raises the possibility that these subtypes also diﬀ er 
in pathogenesis. Indeed, e.g. dopamine levels stay near normal in the ventral internal 
globus pallidum in tremor dominant patients compared to the non-tremor dominant 
subtype and Alzheimer pathology seem to be more prevalent in the subgroup with rapid 
disease progression (43, 44). Th e non-tremor dominant group has signifi cant higher 
grading of cortical Lewy bodies and Braak stages than other subgroups (44, 45). In 
addition, diﬀ erent brain activity patterns between akinetic/rigid and tremor dominant 
subtypes are found, with more involvement of the cerebellum in the tremor dominant 
group and more mesolimbic and amygdala involvement in the akinetic/rigid subgroup 
(46-48). As one can see, most research on dividing PD into subtypes has focused on 
motor symptoms: patient groups with or without tremor, akinetic or rigid patients, 
patients with postural instability or gait diﬃ  culties. However, evidence is emerging that 
non-motor features are also important for defi ning subtypes (49-52).
2.5  Anxiety and depression in the Parkinson spectrum: a subtype?
Although, fi rm evidence is not yet available it is possible that there is a subtype of 
Parkinson’s disease characterized by a high prevalence of both anxiety and depression 
(Chapter 2). Both are, among other non-motor symptoms, associated with the AR/
PIGD motor subtype of PD (4, 53, 54) leading to a constellation of motor symptoms 
including axial rigidity, postural instability and gait diﬃ  culties together with anxiety 
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and depression as the predominant non-motor features: an “Anxiety and depression” 
subtype.  Th is is supported by our earlier mentioned new classifi cation and the fact that 
persistent anxiety is strongly associated with depression, leading to the possibility of a 
single psychiatric syndrome instead of two diﬀ erent entities (34). In addition, in our 
model of anxiety (Chapter 3) depression was far most the strongest marker for anxiety. 
Since anxiety and depression are found consistently more frequent in non-tremor do-
minant subtypes in comparison with the tremor dominant type, it is suggested that the 
non motor features with axial rigidity refl ects defi cits in multiple non-dopaminergic 
transmitter systems, including the cholinergic, noradrenergic and serotonergic systems. 
Th is in contrast to a subtype with pronounced motor complications, which might re-
fl ect predominant involvement of the dopaminergic system (51). Th e fact that PIGD/
AR symptoms and non-motor symptoms generally respond poorly to dopaminergic 
therapy supports this view (49). 
Pathological studies also provide evidence for a ramifi cation of non-motor features in 
diﬀ erent subtypes (55-58). For example, Braak et al. suggested a six-stage system to in-
dicate a predictable sequence of lesions with ascending progression from medullary and 
olfactory nuclei to the cortex, in which the fi rst two presymptomatic stages being related 
to incidental Lewy body disease, stage 3 and 4 with motor symptoms and the last two 
cortical stages with cognitive impairment (56). However, growing evidence exists that 
up to 40% does not follow the proposed caudal-rostral patterns of α-synuclein patho-
logy (59). In addition, classic Braak stages do not correlate with severity of parkinsonism 
or Hoehn and Yahr stages (44). Most studies indicate that the neurodegenerative process 
begins in the brainstem nuclei or the olfactory bulb (60). Progression of neurodegene-
rative disease is than mediated via seeding of misfolded proteins, including α-synuclein 
and tau, which lead to neurodegeneration (61). Diﬀ erences in seeding pathways and 
involved proteins could be an explanation of the diﬀ erences in phenotypes. Recently 
it is shown that diﬀ erent α-synuclein strains seem to cause distinct phenotypes, which 
may explain some of the heterogeneity of the disease (62). It is suggested that a variable 
neuropathological spread is initiated through the olfactory bulb and then spread to 1) 
the limbic system, leading to depression, anxiety, fatigue or pain, or 2) spreading to the 
brainstem which lead to predominantly sleep and autonomic problems or 3) predomi-
nantly spread to the cortex leading to a more cognitive subtype with apathy, dementia 
and frequent falls (49, 50, 55, 58). It is likely that with advancing disease, more overlap 
between diﬀ erent subtypes occur. Some postulated that patients can switch during the 
course of the disease from a tremor dominant type to a non-tremor dominant type (63), 
but others have shown diﬀ erent courses of the distinct subtypes (42).
In line with this concept, depression and persistent anxiety could refl ect a predominant 
involvement of multiple transmitter systems in the brainstem and the limbic system 
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(Figure 1). However, not all depressed or anxious patients have the AR/PIGD motor 
subtype, what makes it unlikely that every anxious or depressed PD patients fi ts the pro-
posed anxiety and depression subgroup. Also, patients with depression without anxiety, 
or anxiety without depression have probably a diﬀ erent underlying etiology. Although 
speculative, it is possible that isolated anxiety is especially episodic and linked to predo-
minantly dopaminergic defi cits, e.g. motor fl uctuations like we found in our model (1, 
33), and appears in already predisposed patients (Figure 2). Th is could be a genetic vul-
nerability or patients with already other risk factors lowering the threshold for acquiring 
an anxiety disorder. Th is is supported by the fact that non-disease specifi c risk factors 
seem to be more important than PD specifi c risk factors in both anxiety and depression 
(Chapter 2). Th e same could be the case for isolated depression, with general risk factors 
already lowering the threshold. However, this concept needs further validation and it is 
clear that subtypes may overlap (50).
Figure 1. 
Different subtypes in Parkinson’s disease, incorporating motor and non-motor symptoms. The “persistent anxiety and 
depression subtype” involves multiple neurotransmitter systems. Figure partly adapted from Sauerbier et al. (50).
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Figure 2. 
Isolated depression or episodic anxiety in predisposed individuals. They predominantly have a late onset and are 
mainly related to dopaminergic deﬁ cits. 
2.6 Implications of the new concept
Th e concept of a distinct etiology of persistent anxiety with depression versus isolated 
depression or anxiety mainly related to psychological factors and motor complications, 
could explain some of the controversies found in past research on motor and non-motor 
features in PD. For example, several risk factors for anxiety have been proposed but 
denied by others. Female gender is associated with anxiety in several studies (1, 4), but 
not in others (33, 64) and disease severity is associated with anxiety in some (64, 65), 
but not all studies (4, 27). As outlined above, it might be possible that the anxiety and 
depression subtype refl ects a more widespread disease, which is likely associated with 
disease severity. On the other hand, isolated depression or anxiety could be the result 
of a psychological reaction in predisposed patients, which is only partly dependent of 
disease severity.  For example, according to the new concept, it is more likely to fi nd a 
signifi cant infl uence of disease severity in studies with mainly patients with persistent 
anxiety and depression, in contrast to studies with mainly patients with isolated depres-
sion or anxiety.
As we showed in chapter 5, a suﬃ  cient study period is important to rule out placebo 
responses in treatment trials. However, the proposed concept could also explain some 
of the disappointing results in treatment trials for depression in PD (66). Treatment 
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both targeting the dopaminergic system (pramipexole (67)) and the serotonergic and/
or noradrenergic system (venlafaxine and paroxetine (2)) seem to have an eﬀ ect in some 
patients but not in others. Sample size was not large enough to identify subject charac-
teristics, but it would be interesting to see if dopaminergic treatment was especially 
eﬀ ective in depressed patients with predominantly motor complications and late onset 
anxiety instead of patients with more non-motor symptoms or AR/PIGD motor symp-
toms. Th e fact that patients with high anxiety scores seem to respond less to paroxetine 
and venlafaxine treatment (68) support the concept of involvement of multiple neurot-
ransmitters, requiring more intensive treatment. Further evidence of diﬀ erent optimal 
treatment choices in specifi c PD subtypes is provided by Katz et al., who also found 
some diﬀ erential eﬀ ects of deep brain stimulation target on motor subtypes in Parkin-
son’s disease (69). 
2.7  Clinical implications and future prospective
We think that it is clinically relevant to include non-motor symptoms alongside motor 
symptoms when subtyping PD. Further understanding of neuropathological hetero-
geneity in the PD spectrum will aid in unraveling this complex disease. It is likely that 
diﬀ erent biological underpinnings will need diﬀ erent treatment strategies. Th erefore, it 
is warranted that future trials divide patients in subgroups based on motor and non-mo-
tor features to identify diﬀ erent trajectories. However, since non-motor subtypes can 
change throughout the course of the disease and subtypes may overlap, large multicen-
ter studies will be necessary with a longitudinal design. Another problem is that latent 
class analysis, currently the most used technique to defi ne subtypes, is dependent on the 
number of included variables. Some studies only used 8 non-motor symptoms, whereas 
others used up to 33 variables (34, 35). In addition, some used symptoms from rating 
scales, where others used DSM criteria.  To this end, it is important to examine an exten-
sive array of non-motor features with their context and relation with motor symptoms 
to create a comprehensive overview of patients’ symptoms. Th e method we examined 
in Chapter 6, the Experience Sampling Method (ESM) could be a valuable tool. ESM 
creates fi ne grain analyses of both motor and non-motor features and gives information 
on how these variables impact each other in the fl ow of daily life on an individual basis. 
In our study, ESM provided with a good feasibility a widespread overview of patients’ 
motor symptoms, contextual factors and aﬀ ective states. Only with a comprehensive 
overview of both non-motor symptoms and motor symptoms detailed subtyping is pos-
sible, and given its possibilities, ESM could become an important method creating this 
overview in future studies. 
2.8 CONCLUSIONS
Anxiety and depression are both frequent in PD. Episodic anxiety with a “late onset” is 
most likely predominantly related to psychological factors in combination with motor 
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fl uctuations whereas an “early onset” may refl ect a neurobiological involvement leading 
to a more persistent state of anxiety. Th e current classifi cation system of anxiety in PD, 
mainly based on DSM criteria does not seem to refl ect true clinical phenotypes. A di-
vision in:
• “Episodic anxiety without depression”
• “Persistent anxiety with depression”
• “Both persistent and episodic anxiety with depression”
fi ts in the proposed new concept of an “anxiety and depression” subtype in the PD 
spectrum. Although further studies are warranted, evidence exists that the clinical he-
terogeneity of PD is based on diﬀ erent neuropathological processes. Th erefore, subty-
pe-directed treatment strategies are needed in a clinically heterogeneous condition as 
PD. Focused treatment on specifi c non-motor- and motor subtypes based on individual 
symptoms, will ultimately aid in optimizing quality of life for PD patients and further 
increase our understanding of the complex PD spectrum.  
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Parkinson’s disease (PD) is the second most common neurodegenerative disease, after 
Alzheimer’s disease. Th e four cardinal motor features upon which the diagnosis of PD 
is based, include bradykinesia, muscle rigidity, resting tremor and postural instabili-
ty. However, PD also encompasses a wide range of non-motor symptoms including 
neuropsychiatric disturbances such as depression and anxiety. Th ese neuropsychiatric 
disturbances are the most frequent non-motor symptoms and occur in up to 67% of PD 
patients. Th ey have a detrimental infl uence on patient’s quality of life, contributing to 
motor symptom severity, motor complications, gait diﬃ  culties, cognitive impairment, 
poor self-perceived health status and even increased mortality. Th is thesis aimed to in-
vestigate conceptual and clinical aspects of anxiety and depression in PD, as well as to 
test the feasibility of a novel method to further unravel the complexity of these non-mo-
tor symptoms in the future. 
Chapter 1 is a general introduction into the theme and aims of this thesis. It provides a 
general background of PD with an emphasis on the non-motor symptoms anxiety and 
depression.
Chapter 2 is a systematic review on the prevalence of anxiety disorders in PD, defi ned 
by DSM criteria and clinically relevant anxiety symptoms assessed by an anxiety rating 
scale. Th e average point prevalence of anxiety disorders in PD was 31%. Generalized 
anxiety disorder was the most frequent disorder, present in 14% of patients, followed 
by social phobia (13.8%), anxiety not otherwise specifi ed (NOS) 13.3%) and specifi c 
phobia (13.0%). Th irty-one percent of patients fulfi lled criteria for current multiple 
anxiety disorders and, based on anxiety rating scale cutoﬀ  scores, clinically signifi cant 
anxiety symptoms were present in a weighted average of 25.7%. Th e review confi rms 
that anxiety, although often unrecognized, is very common and occurs at a higher aver-
age prevalence than depressive disorders in PD (17%). Th is underlines the importance 
for proper identifi cation.
In Chapter 3 we used structural equation modeling (SEM), a methodology for repre-
senting, estimating, and testing a network of relationships between variables. Doing so, 
we explored the relative contribution of PD-specifi c factors (such as more severe motor 
symptoms or motor complications) and nonspecifi c markers (such as history of anxiety 
or female sex) in a model for anxiety in PD.  We found that the PD-specifi c markers 
were the presence of motor fl uctuations and disease-related decline in activities of daily 
living. Nonspecifi c markers were a previous history of depression and the severity of 
the depressive symptoms scored on the Hamilton Depression Rating Scale. Nonspecifi c 
markers had a greater infl uence in the model than PD-specifi c markers of anxiety. Mo-
reover, a post hoc analysis showed that the eﬀ ects of the following variables on anxiety 
were fully mediated via depression: sex, family history of depression, previous history of 
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anxiety, cognitive status, diﬃ  culties in non-disease-specifi c activities of daily living and 
severity of motor signs. Depression was the most prominent marker for anxiety, where 
PD-specifi c markers appeared to be more situational, e.g. related to ‘oﬀ ’ periods and 
disease-specifi c disturbances of activities of daily living.  
In Chapter 4 we investigated the factor structure of the Hamilton Depression Rating 
Scale (HAMD) to explore its multidimensionality in patients with Parkinson’s disease. 
We conducted a principal component analysis of the 17-item HAMD on data of 341 
PD patients. Th e factorial validity of the HAMD was unsatisfactory due to varying 
items per factor, low inter-item correlations within each components and a high percen-
tage of non-redundant residuals and low communality. Th is analysis shows that based 
on factorial structure the HAMD is not appropriate for defi ning specifi c symptom do-
mains of depression for further study.
Since there has been limited research into the domain specifi c magnitude or relative 
timing of treatment response in patients with PD, we studied the diﬀ erential responses 
to antidepressant treatment with venlafaxine or paroxetine in aﬀ ective, somatic and 
cognitive domains of depression in Chapter 5. We found that all symptom domains 
improved during the 12-week study period, although there was a signifi cant placebo 
eﬀ ect in the fi rst two weeks. Compared to placebo, the aﬀ ective symptoms signifi cantly 
improved during treatment as early as week 4, followed by the somatic symptoms of 
depression in week 6 and cognitive symptoms in week 8. Th ese fi ndings could guide 
patient counseling and increase patient compliance by informing about the expected 
treatment responses. In addition, it underlines the importance of a suﬃ  cient long study 
period in future studies since there was a substantial placebo eﬀ ect. 
In Chapter 6 we investigated the feasibility of a novel method to unravel the complex 
relationship between motor symptoms, aﬀ ective states and contextual factors in PD. 
For example, motor symptoms may be more severe when patients are in a public place 
and not at home (contextual factor), with subsequently more anxiety feelings (aﬀ ective 
state). Th e method, known as the Experience Sampling Method (ESM), uses a mobile 
device with a special purpose application to assess motor symptoms, aﬀ ective states 
and contextual factors repeatedly at random moments in the fl ow of daily life. Parti-
cipants achieved a high compliance (84%) and they rated the utility of the device an 
8 on a 10-point scale. We were able to capture extensive diurnal fl uctuations that were 
not revealed by routine clinical assessments. In addition, we detected clinically relevant 
associations between motor symptoms, emotional fl uctuations and contextual factors 
at an intra-individual level. In conclusion, we found that ESM represents a viable and 
novel approach to elucidate relationships between motor symptoms, aﬀ ective states and 
contextual factors at the level of individual subjects. 
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Chapter 7 summarizes and discusses the main fi ndings of this thesis. Th e fi rst part asses-
ses methodological issues of the conducted studies and in the second part the implica-
tion of our fi ndings and recommendations for future research are given on the concept 
and classifi cation of anxiety and depression in PD. Th e current classifi cation system of 
anxiety in PD mainly based on DSM criteria does not seem to refl ect true clinical phe-
notypes. A new concept of an “anxiety and depression” subtype is proposed. Focused 
research and treatment on specifi c non-motor or motor subtypes based on individual 
symptoms, will ultimately aid in optimizing quality of life for PD patients and further 
increase our understanding of the complex PD spectrum.
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De ziekte van Parkinson is, na de ziekte van Alzheimer, de meest voorkomende neurode-
generatieve aandoening. De ziekte wordt gediagnosticeerd op basis van vier motorische 
hoofdsymptomen, te weten bradykinesie (traagheid van bewegen), rigiditeit (stijfheid), 
rusttremor en houdingsinstabiliteit. Echter, de ziekte van Parkinson kenmerkt zich ook 
door een verscheidenheid aan niet-motorische klachten, waaronder neuropsychiatrische 
klachten zoals depressie en angst. Deze neuropsychiatrische klachten  zijn de meest voor-
komende niet-motorische klachten en aanwezig bij 67% van de patiënten. Ze hebben 
een grote invloed op de kwaliteit van leven van de patiënt en dragen onder andere bij 
aan de ernst van de motorische symptomen, motorische complicaties, loopproblemen, 
cognitieve problemen en zelfs tot een hogere mortaliteit. In dit proefschrift worden 
conceptuele en klinische aspecten van angst en depressie bij de ziekte van Parkinson on-
derzocht en beschreven. Daarnaast wordt een nieuwe methode onderzocht die gebruikt 
kan worden om motorische en niet-motorische klachten beter in kaart te brengen. 
In Hoofdstuk 1 wordt een algemeen overzicht gegeven over de ziekte van Parkinson 
met een nadruk op de niet-motorische symptomen angst en depressie. 
In Hoofdstuk 2 worden de bevindingen van een systematisch literatuuroverzicht over 
de prevalentie van angst en angststoornissen bij de ziekte van Parkinson weergegeven. 
Gebaseerd op de DSM-criteria was de gemiddelde puntprevalentie van angststoornissen 
bij patiënten met de ziekte van Parkinson 31%. Het meest frequent was de gegenerali-
seerde angststoornis die bij 14% van de patiënten aanwezig was, gevolgd door de sociale 
fobie (13.8%), de angststoornis niet-anderszins-omschreven (13.3%) en de specifi eke 
fobie (13.0%). Eenendertig procent van de patiënten voldeed aan de criteria voor mul-
tipele angststoornissen. Wanneer er gekeken werd naar scores op angstschalen, bleek 
dat 25.7% van de patiënten klinisch signifi cante angstklachten hadden. Dit overzicht 
bevestigt dat angst, alhoewel vaak niet herkend, veel voorkomend is bij de ziekte van 
Parkinson en het benadrukt het belang van adequate herkenning. 
In Hoofdstuk 3 onderzochten we middels structural equation modeling (SEM), een sta-
tistische methode waarmee verbanden tussen variabelen in een bepaald netwerk worden 
onderzocht, de invloed van PD-specifi eke factoren (zoals de ernst van de motorische 
symptomen of motorische complicaties) en niet-specifi eke factoren (zoals vrouwelijk 
geslacht of een angststoornis in de voorgeschiedenis) op angstklachten. We vonden dat 
de aanwezigheid van motorische fl uctuaties en de ziekte gerelateerde beperkingen in het 
dagelijks functioneren PD-specifi eke markers waren voor het ontwikkelen van angst-
klachten. Niet-specifi eke markers waren een eerder doorgemaakte depressie en de ernst 
van de huidige depressieve symptomen. De niet-specifi eke markers hadden een grotere 
invloed in het angstmodel dan de PD-specifi eke factoren. Daarenboven toonde een 
post hoc analyse aan dat het eﬀ ect op angst van de volgende variabelen geheel geme-
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dieerd werd via de depressie variabele: geslacht, depressieve stoornis bij een familielid, 
een angststoornis in de voorgeschiedenis, cognitief functioneren, niet-ziekte gerelateerde 
beperkingen in het dagelijks functioneren en de ernst van de motorische klachten. Ge-
concludeerd kan worden dat depressie de meest belangrijke risicofactor is voor het ont-
wikkelen van angstklachten. PD-specifi eke risicofactoren lijken met name in bepaalde 
situaties van invloed op de angstklachten, bijvoorbeeld tijdens oﬀ -perioden of bij ziekte 
specifi eke beperkingen in het dagelijks functioneren.
In Hoofdstuk 4 onderzochten we de factorstructuur van de Hamilton Depression Ra-
ting Scale (HAMD), de meest gebruikte depressieschaal bij patiënten met de ziekte van 
Parkinson. Bij het onderzoeken van een factorstructuur probeert men voor een groot 
aantal geobserveerde variabelen (in dit geval de vragen van de HAMD) een kleiner aan-
tal achterliggende variabelen te identifi ceren met gemeenschappelijke kenmerken (de 
factoren). Dit zorgt niet alleen voor datareductie maar ook voor meer inzicht in de struc-
tuur van de data in een bepaalde populatie. Zo kan er gekeken worden of er bepaalde 
symptoomdomeinen te identifi ceren zijn, bijv. een aﬀ ectief domein waarin alle aﬀ ectieve 
symptomen gegroepeerd worden. We verrichtten een principale componentenanalyse 
over de 17 items van de HAMD bij 341 parkinsonpatiënten en vonden dat de factoriële 
validiteit onvoldoende was vanwege wisselende items per factorcomponent, een lage 
inter-item correlatie tussen de componenten en een hoog percentage aan non-redun-
dant residuals en een lage communaliteit. Onze analyse toont aan dat de HAMD niet 
geschikt is voor het onderzoeken van specifi eke symptoomdomeinen van depressie bij 
de ziekte van Parkinson.   
Er is weinig bekend over symptoom specifi eke eﬀ ecten van antidepressiva bij depressieve 
parkinsonpatiënten, alsmede de timing van het behandelingseﬀ ect. In Hoofdstuk 5 
onderzochten we de eﬀ ecten van de antidepressiva venlafaxine en paroxetine op de aﬀ ec-
tieve, somatische en cognitieve symptoomdomeinen van depressie. We concludeerden 
dat symptomen in alle domeinen verbeterden gedurende de 12 weken durende studie-
periode, echter er was een signifi cant placebo-eﬀ ect gedurende de eerste twee weken. 
Vergeleken met de placebogroep, verbeterde de aﬀ ectieve symptomen signifi cant vanaf 
week 4, gevolgd door de somatische symptomen van depressie in week 6 en de cogni-
tieve symptomen in week 8. Onze bevindingen kunnen helpen bij het counselen van 
parkinsonpatiënten tijdens de start van behandeling met een antidepressivum. Uitleg 
over de verwachte respons verhoogt de compliantie. Daarnaast onderstreept deze studie 
het belang van een voldoende lange studieperiode gezien het substantiële placebo-eﬀ ect. 
In Hoofdstuk 6 onderzochten we de geschiktheid van een nieuwe methode om de com-
plexe relatie tussen motorische symptomen, aﬀ ectieve symptomen en contextuele facto-
ren bij de ziekte van Parkinson te ontrafelen. Bij deze methode, de Experience Sampling 
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Method (ESM),  wordt via een mobiele applicatie de ernst van de motorische sympto-
men, aﬀ ectieve symptomen en aan- of afwezigheid van contextuele factoren frequent 
en willekeurig gedurende de dag gescoord, tijdens de dagelijkse bezigheden van de pati-
enten.  Er werd een hoge compliantie (84%) gehaald en de deelnemers scoorden bij de 
gebruiksvriendelijkheid van de applicatie een 8 op een schaal van 10. Door de multipele 
meetpunten per dag was  het mogelijk om fl uctuaties gedurende de dag te monitoren, 
iets wat niet mogelijk is bij de huidige dagelijkse meetmomenten. Daarnaast lukte het 
om klinisch relevante associaties tussen motorische symptomen, emotionele fl uctuaties 
en contextuele factoren te detecteren op een intra-individueel niveau. Concluderend 
vonden we dat de ESM methode een geschikte methode lijkt om in de toekomst de 
complexe relatie tussen motorische symptomen, aﬀ ectieve symptomen en contextuele 
factoren te ontrafelen op een individueel niveau. 
In Hoofdstuk 7 worden de belangrijkste bevindingen van dit proefschrift bediscussieerd. 
Het eerste gedeelte gaat dieper in op de methodologische aspecten van dit proefschrift, 
het tweede gedeelte bevat een beschouwing over de implicatie van onze bevindingen op 
het concept en de classifi catie van angst en depressie bij de ziekte van Parkinson. Het 
huidige classifi catiesysteem van angststoornissen bij de ziekte van Parkinson, gebaseerd 
op DSM criteria, is ontoereikend. Een nieuw concept dat rekening houdt met de ver-
schillende klinische fenotypes, zoals bijvoorbeeld een “angst- en depressie” subtype lijkt 
geïndiceerd. Behandelingen en toekomstige onderzoeken zouden zich moeten richten 
op zowel motorische als niet-motorische subtypes. Dit leidt tot een meer geïndividuali-
seerde aanpak en hopelijk tot een verbetering van de kwaliteit van leven van parkinson-
patiënten. 
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‘Valorisation is the process of creating value from knowledge, by making this knowledge 
available and suitable for economic and social exploitation and to translate this know-
ledge into products, services, processes and new business.’ (1). With other words, it is 
a way in which one can express the importance of research by translating it into social, 
economic and fi nancial value. 
Economic and fi nancial valorisation of this thesis
According to the Dutch Ministry of Health, Wellbeing and Sports, approximately 
29000 patients suﬀ ered from parkinsonism, mostly Parkinson’s disease, in 2011 (2). 
Th is was based on registration by general practitioners, but it is estimated that the true 
prevalence is 2-2.5 times higher (3). In the next decades the median age of the popula-
tion will rise, the number of PD patients will further increase and as such its burden on 
health care services and costs (2). In the Netherlands, health care costs in 2011 for pa-
tients with parkinsonism was estimated to be 267 million euro. Th is encompasses 0.3% 
of Dutch total health care costs and 5.1% of health care costs related to diseases of the 
central nervous system (4). Th e progressive and long-term nature of PD puts a substan-
tial fi nancial burden on patients, spouses and healthcare providers. Next to direct costs 
such as drug costs, in- and outpatients care costs and ancillary treatment, indirect costs 
also impacts fi nancial burden (5). Th e latter includes costs due to lost productivity and 
early retirement. In general, disease severity, motor impairment and motor complicati-
ons appear to have a higher impact on illness costs than non-motor symptoms (NMS) 
(6). However, impairment of patients’ quality of life (QoL) leads to elevation of both 
direct and indirect costs (7). Th is thesis aids in our understanding of both anxiety and 
depression, which are both known to have a high impact on QoL of PD patients (8, 
9). It may be expected that by increasing awareness and recognition with subsequently 
proper treatment, total healthcare costs will eventually decrease.
Social valorization of this thesis
Health related quality of life (HRQoL) is “the perception and evaluation by patients 
themselves of the impact caused on their life by the disease and its consequences”, and 
is crucial in defi ning his/her wellbeing (10). It is well known that PD has a high impact 
on quality of life (11). HRQoL is not only aﬀ ected by motor symptoms, but there is 
increasing evidence that the occurrence of various non-motor symptoms (NMS) also 
play an important role in HRQoL perception of PD patients (12, 13). In addition, 
a recent study showed that despite having progressive motor impairment, non-motor 
symptoms provided a better prediction of the change of HRQoL over time than motor 
symptoms (14). Among the NMS with the highest impact on HRQoL are depression, 
anxiety, urinary disturbances, pain, fatigue and sleep problems (15-17). Especially de-
pression is one of the most signifi cant determinants of HRQoL, although some found 
that anxiety is even more so (8, 9). Next to the eﬀ ect of anxiety and depression on the 
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patient themselves, it also has a high impact on caregivers. Th ey experience distress 
and problems on physical, mental and socioeconomic aspects of their lives (18). For 
example, a PD patients’ depression seems to be strongly correlated with the presence 
of depressive symptoms in the caregiver (19). Emotional strain of caregivers even con-
tributes to mortality (20) and in PD it leads to higher patient institutionalization with 
subsequently higher health care costs (21). Especially neuropsychiatric symptoms, such 
as anxiety and depression, are identifi ed as predictors of caregiver burden (18, 22-24). 
Increasing the awareness of the high prevalence of anxiety in PD (Chapter 2) and trying 
to identify markers (Chapter 3) hopefully lead to earlier treatment. In addition, incor-
porating new diagnostic and monitoring tools (Chapter 6), improving rating scales of 
depression (Chapter 4) and informing depressed PD patients about the expected treat-
ment response (Chapter 5) will likely improve identifi cation and treatment compliance. 
Improved recognition, reporting and management of anxiety and depression positively 
aﬀ ect the HRQoL of patients with PD and their caregivers.
Products and processes
Th e application we studied in chapter 6, the Experience Sampling Method seems to be 
a viable and useful method to study infl uences of motor symptoms, aﬀ ective states and 
contextual factors in PD patients. Th e ESM software is freeware and can be downloa-
ded for free as an app on smartphones or iPods. By implementing this method in daily 
practice, it enables the recognition of highly individual patters and aids in unraveling in-
tra-individual relations between motor and non-motor symptoms. Th ese person-specifi c 
patters may be fed back to the subject to enhance insight into factors associated with 
symptom severity and even more importantly facilitate self-management.  Behavioral 
insight may enhance feelings of mastery over the symptoms and facilitate coping or ad-
justment of activities. Second, ESM can be used to monitor the treatment progress and 
drug side eﬀ ects, revealing relatively small treatment eﬀ ects by avoiding clouding due to 
recall bias when using retrospective self-report measures.  Last, ESM captures subjective 
experiences of PD patients, which can diﬀ er from more objective tools like the UPDRS 
scale. However, self-reports may be a more useful source of data when dealing with 
immediate experiences such as aﬀ ective states. In addition, combining ESM with an 
accelerometer will give both objective and subjective measures, providing an extensive 
overview of symptom patterns on an individual base. As mentioned in the discussion 
(Chapter 7), this is needed for optimizing treatment strategies in a heterogeneous illness 
such as PD. 
Conclusion
Th is thesis can help neurologists, psychiatrists, psychologists, general practitioners and 
PD patients and their spouses in their understanding of anxiety and depression in PD. 
Highlighting the high prevalence of anxiety in PD hopefully increase its awareness. Th e 
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markers identifi ed in our model can aid in recognizing anxiety and specialists should 
search for clinically relevant anxiety in depressed PD patients. With testing depression 
rating scales and studying treatment responses in depressed PD patients we hopefully 
help to optimize recognition and treatment compliance. Treatment strategies must focus 
on individual patients and ESM seem to be a feasible tool to monitor and study PD 
symptoms and treatment responses. When this is accomplished, HRQoL of PD patients 
and their spouses will increase and health related costs will likely decline. 
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nooit zover gekomen. Jullie hebben altijd de vrijheid gelaten om mijzelf te ontwikkelen 
en zo nodig hebben jullie mij ondersteund of aangestuurd. Op de momenten dat het 
nodig was kon ik altijd op jullie rekenen, jullie hebben geen idee hoe fi jn ik dat vond. 
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Ik hoop dat we nog vaak samenzijn op de manier hoe moeder het zou omschrijven: “full 
house” .
Ook al staan we nog in het begin, het voelt heel goed. Dank voor alle ontspannende en 
leuke momenten, ik hoop dat er nog veel mogen volgen..
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